var title_f18_20_18752="Billroth II variations";
var content_f18_20_18752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Billroth II gastrectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the different configurations that may be encountered in patients who have undergone Billroth II reconstruction. In panel A, a large anastomosis results in wide separation of the jejunal limbs compared to the smaller anastomosis in panel B. Panel C demonstrates that the location of the afferent and efferent limbs relative to one another can vary, although the afferent limb is often closer to the lesser curvature as illustrated in panels A and B.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18752=[""].join("\n");
var outline_f18_20_18752=null;
var title_f18_20_18753="MRI cervical spondylosis";
var content_f18_20_18753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI cervical spondylosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18753=[""].join("\n");
var outline_f18_20_18753=null;
var title_f18_20_18754="Patient information: Scoliosis (The Basics)";
var content_f18_20_18754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83174\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/59/21439\">",
"         Scoliosis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/51/22320\">",
"         Patient information: Back pain in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Scoliosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/scoliosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27682331\">",
"      <span class=\"h1\">",
"       What is scoliosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Scoliosis is a condition that makes the spine (backbone) curve sideways, like the letter &ldquo;S&rdquo; or &ldquo;C.&rdquo; Often, the spine also twists so the back is not flat. If the spine twists, 1 side of the back sticks out more than the other (",
"      <a class=\"graphic graphic_picture graphicRef56860 \" href=\"UTD.htm?20/59/21439\">",
"       picture 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Scoliosis usually starts to happen as the spine is growing, in childhood or during the teenage years. A birth defect, disease, or injury can cause scoliosis. It might also run in families. But in many cases, doctors do not know what causes scoliosis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27682346\">",
"      <span class=\"h1\">",
"       What are the symptoms of scoliosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Scoliosis usually does not cause symptoms. A doctor or nurse might find it when a child gets a routine checkup. Or the school nurse might notice it during a scoliosis check at school. &nbsp;",
"     </p>",
"     <p>",
"      You, your child or teenager might also notice:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A shoulder, shoulder blade, hip, or breast that is higher than the other",
"       </li>",
"       <li>",
"        A shoulder blade that sticks out farther than the other",
"       </li>",
"       <li>",
"        A skin fold on 1 side of the waist",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When symptoms do occur, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Back pain",
"       </li>",
"       <li>",
"        Trouble breathing &ndash; If the spine curves a lot, the lungs might not have room to work correctly. This can cause breathing problems. Scoliosis this severe usually starts when a child is younger than 10. The scoliosis is usually obvious before breathing problems happen.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27682361\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your child&rsquo;s symptoms. See a doctor or nurse right away if your child limps, does not want to walk, or has 1 leg that feels weak. Make an appointment to see the doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Everyday activities make your child&rsquo;s back hurt.",
"       </li>",
"       <li>",
"        Your child has severe back pain, or back pain that gets worse over time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27682376\">",
"      <span class=\"h1\">",
"       Is there a test for scoliosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are several tests. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Forward bend test &ndash; This test shows if the spine is twisted so 1 side of the back is higher than the other. The doctor or nurse can also measure how much the spine is twisted.",
"       </li>",
"       <li>",
"        X-ray &ndash; An X-ray of the spine can show how much the spine curves from side to side. Other kinds of X-rays can show if the scoliosis is likely to get worse as the child grows. An X-ray can also help the doctor tell if another problem in the body is causing the scoliosis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on the situation, the doctor might also order a test called an &ldquo;MRI.&rdquo; This imaging test creates pictures of the inside of the body. The pictures show more detail than an X-ray. &nbsp;",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor or nurse will do an exam and ask questions. Along with tests, this should tell the doctor or nurse if your child has scoliosis and what is causing it. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27682391\">",
"      <span class=\"h1\">",
"       How is scoliosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment is different for each person. Mild scoliosis does not need to be treated. But severe scoliosis can cause breathing problems and heart problems. People with severe scoliosis need treatment.",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor will decide about treatment based on whether the scoliosis is likely to get worse or not. Treatment options include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        No treatment &ndash; If a child is finished growing and the spine does not curve a lot, treatment is usually not needed.",
"       </li>",
"       <li>",
"        Watchful waiting &ndash; If a child is NOT finished growing but the scoliosis is not severe, the doctor might suggest watching for changes. The child might need to see a specialist if the doctor or nurse cannot tell exactly how much the spine curves or if the scoliosis starts getting worse.",
"       </li>",
"       <li>",
"        Bracing &ndash; A child might need a brace that helps straighten the spine if:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        He or she still has a lot of growing to do, and",
"       </li>",
"       <li>",
"        The scoliosis gets worse in 6 months or less",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; If the spine curves a lot, the doctor might recommend surgery even if a child is done growing. This is because severe scoliosis usually gets worse with time. The surgery joins vertebrae (bones in the spine) together to help them line up correctly. This can keep the curve from getting worse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27682406\">",
"      <span class=\"h1\">",
"       What if my daughter wants to have children in the future?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Scoliosis does not usually cause problems with pregnancy and giving birth. In the past, some doctors thought pregnancy made scoliosis worse. Today, doctors know this does not happen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27682423\">",
"      <span class=\"h1\">",
"       Can my child live a normal life?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Most people with scoliosis do not have long lasting problems. A few people have back pain, but it is usually not serious.",
"     </p>",
"     <p>",
"      Severe scoliosis that is not treated can damage the heart and lungs. If scoliosis is caused by a serious medical condition, that condition can cause problems, too. Your doctor or nurse will watch for problems and treat them if they happen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27682440\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/51/22320?source=see_link\">",
"       Patient information: Back pain in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/20/18754?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83174 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18754=[""].join("\n");
var outline_f18_20_18754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682331\">",
"      What is scoliosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682346\">",
"      What are the symptoms of scoliosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682361\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682376\">",
"      Is there a test for scoliosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682391\">",
"      How is scoliosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682406\">",
"      What if my daughter wants to have children in the future?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682423\">",
"      Can my child live a normal life?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27682440\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/59/21439\">",
"      Scoliosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/51/22320?source=related_link\">",
"      Patient information: Back pain in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_20_18755="Hemin: Patient drug information";
var content_f18_20_18755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hemin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     see \"Hemin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Panhematin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acute intermittent porphyria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hemin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation or swelling where the shot was given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at home, follow how to store as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11751 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18755=[""].join("\n");
var outline_f18_20_18755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178696\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026054\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026053\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026058\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026059\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026061\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026056\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026057\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026062\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026063\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=related_link\">",
"      Hemin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_20_18756="Hepatic venogram";
var content_f18_20_18756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Hepatic venogram obtained during transjugular liver biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hepatic venogram after selective catheterization of the right hepatic vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18756=[""].join("\n");
var outline_f18_20_18756=null;
var title_f18_20_18757="Ibritumomab: Patient drug information";
var content_f18_20_18757=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ibritumomab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     see \"Ibritumomab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zevalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zevalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some patients have very bad side effects during the infusion. Tell your doctor if you have any bad effects during the infusion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad rashes have been reported. Talk with your doctor right away if you get a rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ibritumomab, rituximab, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to mouse proteins or yttrium chloride, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for 12 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 12 months after care ends. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696046",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with a drug called rituximab.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10752 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18757=[""].join("\n");
var outline_f18_20_18757=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181392\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663220\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013845\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013847\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013846\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013851\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013852\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013854\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013849\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013856\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=related_link\">",
"      Ibritumomab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_20_18758="Remote afterloader";
var content_f18_20_18758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Remote afterloader for high dose rate (HDR) brachytherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A remote afterloader stores a single high dose rate (HDR) radioactive source, typically Iridium-192, and through a computer controlled mechanism advances it within the catheter or applicator that has been placed in the patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18758=[""].join("\n");
var outline_f18_20_18758=null;
var title_f18_20_18759="Diagnosis and treatment of pulmonary alveolar proteinosis in adults";
var content_f18_20_18759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of pulmonary alveolar proteinosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18759/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18759/contributors\">",
"     Edward D Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18759/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18759/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18759/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/20/18759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary alveolar proteinosis (PAP), also known as pulmonary alveolar phospholipoproteinosis, is a diffuse lung disease characterized by the accumulation of amorphous, periodic acid-Schiff (PAS)-positive lipoproteinaceous material in the distal air spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptoms are dyspnea and cough. Radiographic imaging typically reveals bilateral symmetric alveolar opacities located centrally in mid and lower lung zones, often in a \"bat wing\" distribution. Three forms of PAP are recognized: congenital, secondary, and acquired (",
"    <a class=\"graphic graphic_table graphicRef77313 \" href=\"UTD.htm?14/8/14475\">",
"     table 1",
"    </a>",
"    ). A more detailed discussion of the etiology and clinical manifestations of PAP is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will provide an approach to the diagnosis and treatment of PAP. General approaches to adult and pediatric interstitial lung disease are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our diagnostic algorithm for suspected PAP is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef71438 \" href=\"UTD.htm?31/48/32526\">",
"     algorithm 1",
"    </a>",
"    ). When findings suggestive of PAP are noted on HRCT scan in patients with a compatible clinical presentation, we proceed to fiberoptic bronchoscopy to obtain bronchoalveolar lavage (BAL) fluid and, when possible, transbronchoscopic biopsies. Unless contraindicated, transbronchoscopic biopsies should be obtained following the BAL procedure. The diagnosis of PAP is confirmed with a positive PAS stain from BAL or transbronchial biopsy. To exclude the presence of concurrent infection, special stains and cultures for opportunistic infections (eg, Nocardia, mycobacteria, fungi) are also obtained during bronchoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\", section on 'Associated infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A transbronchial or surgical lung biopsy is the definitive diagnostic test for PAP. In many cases, the diagnostic accuracy of PAS staining of fluid obtained by BAL and tissue obtained by transbronchial biopsy has obviated the need for open or thoracoscopic lung biopsy when clinical and CT findings are consistent with the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. As an example, in the largest series, the diagnosis was made by HRCT and BAL in 59 percent; HRCT, BAL and transbronchial biopsy in 34 percent; and video-assisted transthoracic biopsy in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also normally obtain a complete blood count and differential because of the occasional association of PAP with hematologic malignancies. In addition, we usually measure serum lactic dehydrogenase (LDH), as this correlates with disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/8\">",
"     8",
"    </a>",
"    ]. Pulmonary function tests, including lung volumes, diffusing capacity, and six-minute-walk, are used to assess the degree of impairment and for long-term monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\", section on 'Pulmonary function tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anti-GM-CSF titer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of BAL or serum anti-GM-CSF antibody may be helpful in the evaluation of adults with acquired PAP. In the absence of any known secondary cause of PAP, an elevated serum anti-GM-CSF titer is 100 percent sensitive and 91 to 98 percent specific for the diagnosis of acquired PAP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. BAL fluid levels of anti-GM-CSF antibodies correlate better with the severity of PAP compared to serum titers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/12\">",
"     12",
"    </a>",
"    ]. Serial measurements of BAL or serum anti-GM-CSF antibodies may prove useful in monitoring disease activity and response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of adult PAP involves those disorders with similar radiographic manifestations. These include acute silicosis, pneumonia (eg, due to Pneumocystis jirovecii (formerly carinii) and Nocardia), acute respiratory distress syndrome, lipoid pneumonia, acute interstitial pneumonia, drug-related hypersensitivity reactions, and diffuse alveolar damage superimposed on usual interstitial pneumonitis (UIP).",
"   </p>",
"   <p>",
"    PAP is likely if abundant PAS positive proteinaceous material is found in and around alveolar macrophages in lavage fluid (",
"    <a class=\"graphic graphic_picture graphicRef78010 \" href=\"UTD.htm?16/33/16927\">",
"     picture 1",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flocculent and granular PAS positive lipoproteinaceous material stain is demonstrated filling terminal bronchioles and alveoli on lung biopsy (",
"    <a class=\"graphic graphic_picture graphicRef80653 \" href=\"UTD.htm?24/16/24840\">",
"     picture 2",
"    </a>",
"    ). Secondary causes of alveolar proteinosis are usually identified by history of inhalational exposure (eg, silica, titanium, or aluminum), positive stains",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cultures obtained from bronchoscopy (eg, Pneumocystis jirovecii or Nocardia), or presence of leukemic cells in the peripheral blood.",
"   </p>",
"   <p>",
"    In addition to the absence of PAS positive proteinaceous material on BAL, the following features help to distinguish among the alternative diagnostic possibilities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical presentation of fulminant respiratory failure with diffuse alveolar opacities would favor acute respiratory distress syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      BAL demonstration of large numbers of lipid-laden macrophages would suggest lipoid pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"       \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The HRCT appearance of a predominantly subpleural distribution of disease and sparse honeycombing would favor acute interstitial pneumonia and the BAL would be negative on PAS stain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=see_link\">",
"       \"Acute interstitial pneumonia (Hamman-Rich syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced pneumonitis should be suspected in patients with exposure to medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      . (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      The radiographic features of diffuse alveolar damage superimposed on UIP would include subpleural septal thickening and honeycombing that would not be features of PAP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of treatment options for PAP depends upon the severity of disease. This is based on observations about the natural history of the disease that show a high rate of spontaneous remission. In the largest series, for example, asymptomatic patients were most likely to have a stable to improving course with only 8 percent worsening during follow up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/8\">",
"     8",
"    </a>",
"    ]. Among symptomatic patients, the proportions with stable, improved, and worsening disease were about 45, 30, and 25 percent, respectively. Patients with longer disease duration were more likely to have progressive disease.",
"   </p>",
"   <p>",
"    In order to obtain the best risk benefit balance when choosing therapy, we divide patients into the following three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic with or without mild physiologic abnormalities (eg, a mild reduction in diffusing capacity and only minimal oxygen desaturation on exertion)",
"     </li>",
"     <li>",
"      Mild to moderate symptoms (eg, dyspnea on moderate exertion) and physiologic abnormalities (eg, requiring supplemental oxygen with exercise)",
"     </li>",
"     <li>",
"      Moderate to severe symptoms (eg, dyspnea with minimal exertion or at rest) and physiologic abnormalities (eg, requiring supplemental oxygen at rest)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these categories, we advise the following approach to treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are asymptomatic with little or no physiologic impairment do not require immediate treatment and can be observed with periodic reassessment of symptoms, pulmonary function tests, and chest imaging.",
"     </li>",
"     <li>",
"      For patients with mild symptoms, mild hypoxemia on exertion, and normoxia at rest, supportive therapy with supplemental oxygen is appropriate; such patients require ongoing monitoring as described above to identify any further deterioration.",
"     </li>",
"     <li>",
"      Patients who have moderate to severe disease based on symptoms and physiologic testing may elect to proceed with whole lung lavage or a trial of experimental treatment (eg, subcutaneous GM-CSF, plasmapheresis). These options are described in the sections that follow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Whole lung lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have moderate to severe symptoms and hypoxemia, whole lung lavage under general anesthesia via a double-lumen endotracheal tube is the most widely accepted and effective form of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Specific indications for lung lavage include a definitive histologic diagnosis and one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resting PaO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;65 mmHg (at sea level)",
"     </li>",
"     <li>",
"      Alveolar-arterial O",
"      <sub>",
"       2",
"      </sub>",
"      gradient &ge;40 mmHg",
"     </li>",
"     <li>",
"      Measured shunt fraction &gt;10 to 12 percent",
"     </li>",
"     <li>",
"      Severe dyspnea and hypoxemia at rest or on exercise",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technique of whole lung lavage is well described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In brief, the patient is anesthetized and paralyzed in the operating room. A double-lumen endotracheal tube is inserted, and one lung is lavaged with warmed (37&ordm;C) saline while the other lung is independently ventilated and oxygenated. Generally, aliquots of 1 to 1.5 liters of warm saline are required for each lavage, and a total of approximately 10 to 15 lavages are used for clearing of the lavage effluent from each lung (",
"    <a class=\"graphic graphic_picture graphicRef82575 \" href=\"UTD.htm?9/45/9936\">",
"     picture 3",
"    </a>",
"    ). Chest percussion during the lavage procedure significantly increases the recovery of the lipoproteinaceous material [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/20\">",
"     20",
"    </a>",
"    ]. Bilateral sequential whole lung lavage has been performed in a single treatment session.",
"   </p>",
"   <p>",
"    Meticulous charting and monitoring of oxygenation, dynamic lung compliance, correct position of the double-lumen endotracheal tube, and recovery of the infused saline are necessary to avoid and to quickly diagnose complications. Complications of whole lung lavage include malpositioning of the endotracheal tube, saline spillover into the unlavaged ventilated lung, and hydropneumothorax.",
"   </p>",
"   <p>",
"    After whole lung lavage, patients often feel dramatically better, with improvement in exertional dyspnea. The clinical course is variable. Thirty to 40 percent of patients require only one lavage, while others require repeat lung lavages at intervals of 6 to 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Granulocyte macrophage-colony stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental therapy with granulocyte macrophage-colony stimulating factor (GM-CSF) has been used in patients with PAP, based on evidence that reduced GM-CSF effect (eg, due to altered receptor function or antibodies) contributes to PAP. Preliminary data suggests that the proportion of responders to GM-CSF is less than with whole lung lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Given the experimental nature of GM-CSF therapy, we use lung lavage as primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/21,22,25-28\">",
"     21,22,25-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\", section on 'Role of GM-CSF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an open label trial of 25 patients, recombinant human GM-CSF was given subcutaneously, starting at 250",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    for one month, increasing to 5",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    for the second month, and 9",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    for the third month. Responders were continued on this dose for 12 months; those with a suboptimal clinical response were given further dose escalations up to 18",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/22\">",
"     22",
"    </a>",
"    ]. Overall, 48 percent experienced symptomatic and radiographic improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many patients with acquired PAP do not manifest a normal hematologic response to GM-CSF; very high doses of the cytokine may be required to achieve a modest elevation in the white blood cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/23,29\">",
"     23,29",
"    </a>",
"    ]. Dyspnea, spirometry, diffusing capacity, ambulatory oximetry, and chest CT scan are monitored to assess the response to therapy. Normal serum lactate dehydrogenase (LDH) and declining anti-GM-CSF antibody levels may predict a positive response to GM-CSF therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/13,28\">",
"     13,28",
"    </a>",
"    ]. The most common side effects are fever, fatigue, headache, and injection site pain, redness, and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhalation of nebulized GM-CSF has been reported to improve lung function and facilitate clearance of the GM-CSF-antibody complex from the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/24,30-32\">",
"     24,30-32",
"    </a>",
"    ]. In an open label study of adults with PAP, GM-SF was administered by inhalation to 35 patients twice daily for 8 of 14 days for 12 weeks, followed by once daily therapy for 4 of 14 days for another 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared with an initial observation period, gas exchange improved in 24 patients over the 24 weeks of inhalation therapy. Over the 52 week follow-up period, 29 patients remained stable; three underwent whole lung lavage; and three received additional inhaled GM-CSF with improvement. Initial levels of anti-GM-CSF autoantibodies were not different between responders and nonresponders. In a follow-up study, GM-CSF inhalation was associated with a decrease in anti-GM-CSF autoantibodies in the bronchoalveolar lavage fluid from improved patients, but not in the serum, suggesting that GM-CSF inhalation might not affect autoantibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation has been performed in patients who deteriorate despite whole lung lavage, but recurrence in the allograft has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/34\">",
"     34",
"    </a>",
"    ]. Treatment with plasmapheresis and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    have yielded mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/13,14,35-37\">",
"     13,14,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no role for glucocorticoids or other immunosuppressive agents as primary therapy for PAP; glucocorticoids may actually increase mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/38\">",
"     38",
"    </a>",
"    ]. Allogeneic bone marrow transplantation has reversed PAP in GM-CSF receptor-deficient mice and has been suggested (but not yet undertaken) in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PAP may wish to participate in a clinical trial (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , GM-CSF). Additional information is available at",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     file://clinicaltrials.gov",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis of PAP has not been extensively described. One series of 24 patients with a mean follow-up of 8.5 years found that six patients died (none from complications of PAP), and that approximately 50 percent of the survivors had persistent symptoms, such as dyspnea, cough, chest pain, or wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/40\">",
"     40",
"    </a>",
"    ]. A separate report that assessed long-term outcome in 21 patients treated with whole lung lavage noted a recurrence rate of &lt;30 percent; however, the number of patients was small, and residual gas exchange abnormalities and exercise intolerance were common, even in the absence of recurrent PAP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fact that some patients with acquired PAP have a self-limited course has led to the hypothesis that some cases of PAP result from an acquired clonal disorder of hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18759/abstract/29\">",
"     29",
"    </a>",
"    ]. Remission may result from subsequent displacement of this abnormal clone from the hematopoietic pool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When findings typical of pulmonary alveolar proteinosis (PAP) are noted on chest radiograph and high resolution computed tomography (HRCT) in a patient with a compatible clinical presentation, we proceed to fiberoptic bronchoscopy to obtain bronchoalveolar lavage (BAL) and, if possible, transbronchoscopic biopsy (",
"      <a class=\"graphic graphic_algorithm graphicRef71438 \" href=\"UTD.htm?31/48/32526\">",
"       algorithm 1",
"      </a>",
"      ). In the occasional patient with negative BAL and transbronchoscopic biopsy, video-assisted transthoracic biopsy is the next step. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical BAL fluid has an opaque or milky appearance due to abundant lipoproteinaceous material. Cytologic examination of BAL reveals alveolar macrophages engorged with PAS-positive material. Transbronchial and open lung biopsies reveal filling of the terminal bronchioles and alveoli with flocculent and granular lipoproteinaceous material that stains pink with PAS stain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults with a strong suspicion for or diagnosis of PAP should have serologic testing for antibodies to granulocyte macrophage-colony stimulating factor (GM-CSF). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anti-GM-CSF titer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of treatment options for patients with PAP depends on the severity of symptoms and gas exchange abnormalities. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are asymptomatic with little or no physiologic impairment despite extensive radiographic abnormalities, we recommend a period of observation rather than specific therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild symptoms, normoxia at rest, and exercise related hypoxemia, we prefer supportive care with supplemental oxygen, as needed, to more invasive therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe dyspnea and hypoxemia, we recommend whole lung lavage via a double-lumen endotracheal tube (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Specific indications for lung lavage include a definitive histologic diagnosis and evidence of severe dyspnea and hypoxemia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Whole lung lavage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of GM-CSF subcutaneously or by inhalation for idiopathic PAP remains experimental, but may be an option for adults with idiopathic PAP who cannot undergo or have not responded to whole lung lavage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Granulocyte macrophage-colony stimulating factor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using glucocorticoids for PAP, as these are not beneficial (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other therapies such as lung transplantation and plasmapheresis have been performed in individual patients; further data are needed before recommending these options. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who wish to participate in a clinical trial, additional information is available at",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"       file://clinicaltrials.gov",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/1\">",
"      Shah PL, Hansell D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/2\">",
"      Kariman K, Kylstra JA, Spock A. Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years. Lung 1984; 162:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/3\">",
"      Milleron BJ, Costabel U, Teschler H, et al. Bronchoalveolar lavage cell data in alveolar proteinosis. Am Rev Respir Dis 1991; 144:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/4\">",
"      Rubinstein I, Mullen JB, Hoffstein V. Morphologic diagnosis of idiopathic pulmonary alveolar lipoproteinosis-revisited. Arch Intern Med 1988; 148:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/5\">",
"      Burkhalter A, Silverman JF, Hopkins MB 3rd, Geisinger KR. Bronchoalveolar lavage cytology in pulmonary alveolar proteinosis. Am J Clin Pathol 1996; 106:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/6\">",
"      Masuda T, Shimura S, Sasaki H, Takishima T. Surfactant apoprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis. Lancet 1991; 337:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/7\">",
"      Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest 1997; 111:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/8\">",
"      Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/9\">",
"      Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 162:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/10\">",
"      Bonfield TL, Russell D, Burgess S, et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/11\">",
"      Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009; 113:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/12\">",
"      Lin FC, Chang GD, Chern MS, et al. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax 2006; 61:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/13\">",
"      Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/14\">",
"      Luisetti M, Rodi G, Perotti C, et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009; 33:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/15\">",
"      Claypool WD, Rogers RM, Matuschak GM. Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest 1984; 85:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/16\">",
"      LARSON RK, GORDINIER R. PULMONARY ALVEOLAR PROTEINOSIS. REPORT OF SIX CASES, REVIEW OF THE LITERATURE, AND FORMULATION OF A NEW THEORY. Ann Intern Med 1965; 62:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/17\">",
"      Beccaria M, Luisetti M, Rodi G, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004; 23:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/18\">",
"      Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med 2011; 105:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/19\">",
"      Borie R, Danel C, Debray MP, et al. Pulmonary alveolar proteinosis. Eur Respir Rev 2011; 20:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/20\">",
"      Hammon WE, McCaffree DR, Cucchiara AJ. A comparison of manual to mechanical chest percussion for clearance of alveolar material in patients with pulmonary alveolar proteinosis (phospholipidosis). Chest 1993; 103:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/21\">",
"      Kavuru MS, Sullivan EJ, Piccin R, et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/22\">",
"      Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006; 130:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/23\">",
"      Latzin P, Tredano M, W&uuml;st Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/24\">",
"      Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/25\">",
"      Seymour JF, Dunn AR, Vincent JM, et al. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med 1996; 335:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/26\">",
"      Barraclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax 2001; 56:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/27\">",
"      de Vega MG, S&aacute;nchez-Palencia A, Ram&iacute;rez A, et al. GM-CSF therapy in pulmonary alveolar proteinosis. Thorax 2002; 57:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/28\">",
"      Seymour JF, Doyle IR, Nakata K, et al. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003; 58:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/29\">",
"      Seymour JF, Begley CG, Dirksen U, et al. Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Blood 1998; 92:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/30\">",
"      Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005; 171:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/31\">",
"      Wylam ME, Ten R, Prakash UB, et al. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006; 27:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/32\">",
"      Robinson TE, Trapnell BC, Goris ML, et al. Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest 2009; 135:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/33\">",
"      Ohashi K, Sato A, Takada T, et al. Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. Eur Respir J 2012; 39:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/34\">",
"      Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/35\">",
"      Kavuru MS, Bonfield TL, Thomassen MJ. Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Respir Crit Care Med 2003; 167:1036; author reply 1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/36\">",
"      Borie R, Debray MP, Laine C, et al. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009; 33:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/37\">",
"      Amital A, Dux S, Shitrit D, et al. Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis. Thorax 2010; 65:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/38\">",
"      Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/39\">",
"      Gaine SP, O'Marcaigh AS. Pulmonary alveolar proteinosis: lung transplant or bone marrow transplant? Chest 1998; 113:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18759/abstract/40\">",
"      Goldstein LS, Kavuru MS, Curtis-McCarthy P, et al. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest 1998; 114:1357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4356 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18759=[""].join("\n");
var outline_f18_20_18759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anti-GM-CSF titer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Whole lung lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Granulocyte macrophage-colony stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4356|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/48/32526\" title=\"algorithm 1\">",
"      Alveolar proteinosis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4356|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/33/16927\" title=\"picture 1\">",
"      PAS stain of BAL fluid in alveolar proteinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/16/24840\" title=\"picture 2\">",
"      Histopathology of pulmonary alveolar proteinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/45/9936\" title=\"picture 3\">",
"      Bronchoalveolar lavage in PAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/8/14475\" title=\"table 1\">",
"      Causes alveolar proteinosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22792?source=related_link\">",
"      Acute interstitial pneumonia (Hamman-Rich syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_20_18760="Captopril: Pediatric drug information";
var content_f18_20_18760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Captopril: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"    see \"Captopril: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=see_link\">",
"    see \"Captopril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Capto&reg;;",
"     </li>",
"     <li>",
"      Capoten&reg;;",
"     </li>",
"     <li>",
"      Dom-Captopril;",
"     </li>",
"     <li>",
"      Mylan-Captopril;",
"     </li>",
"     <li>",
"      Nu-Capto;",
"     </li>",
"     <li>",
"      PMS-Captopril;",
"     </li>",
"     <li>",
"      Teva-Captopril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Heart failure (afterload reduction); hypertension:",
"     </b>",
"     Limited data available:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage must be titrated according to patient's response; use lowest effective dose; lower doses (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of those listed) should be used in patients who are sodium and water depleted due to diuretic therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Premature neonates: Oral: Initial: 0.01 mg/kg/dose every 8-12 hours; titrate dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Term neonates, PNA &le;7 days: Oral: Initial: 0.01 mg/kg/dose every 8-12 hours; titrate dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Term neonates, PNA &gt;7 days: Oral: Initial: 0.05-0.1 mg/kg/dose every 8-24 hours; titrate dose upward to maximum of 0.5 mg/kg/dose given every 6-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"      see \"Captopril: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Heart failure (afterload reduction):",
"     </b>",
"     Limited data available:",
"     <b>",
"      Note:",
"     </b>",
"     Initiate therapy at lower end of range and titrate upward to prevent symptomatic hypotension (Momma, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: Oral: 0.3-2.5 mg/kg/day divided every 8-12 hours; one study of infants (age: 1-7 months) with left-right shunt reported a mean dose of 1.3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents: Oral: 0.3-6 mg/kg/day divided every 8-12 hours; maximum daily dose: 150 mg/",
"     <b>",
"      day",
"     </b>",
"     ; in clinical trials, usual reported dosage range was 0.9-3.9 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Limited data available:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage must be titrated according to patient's response; use lowest effective dose; lower doses (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of those listed) should be used in patients who are sodium- and water-depleted due to diuretic therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-based dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants: Oral: Initial: 0.15-0.3 mg/kg/dose; titrate dose upward to maximum of 6 mg/kg/day in 1-4 divided doses; usual required dose: 2.5-6 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children and Adolescents: Oral: Initial: 0.3-0.5 mg/kg/dose every 8 hours; may titrate as needed up to maximum daily dose: 6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses (NHBPEP, 2004; NHLBI, 2011); maximum daily dose: 450 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fixed dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Older Children: Oral: Initial: 6.25-12.5 mg/dose every 12-24 hours; titrate as needed; maximum daily dose: 6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 2-4 divided doses; maximum daily dose: 450 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents: Oral: Initial: 12.5-25 mg/dose given every 8-12 hours; increase by 25 mg/dose at 1-2 week intervals based on patient response; maximum daily dose: 450 mg/",
"     <b>",
"      day",
"     </b>",
"     ; usual dosage range for hypertension (JNC 7): Adolescents &ge;18 years: 25-100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose according to patient's response; use lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute hypertension (urgency/emergency):",
"     </b>",
"     Oral: 12.5-25 mg, may repeat as needed (may be given sublingually, but no therapeutic advantage demonstrated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial dose: 6.25-12.5 mg 3 times daily in conjunction with cardiac glycoside and diuretic therapy; initial dose depends upon patient's fluid/electrolyte status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Target dose: 50 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial dose: 25 mg 2-3 times daily [a lower initial dose of 12.5 mg 3 times daily may also be considered (VA Cooperative Study Group, 1984)]; may increase by 12.5-25 mg/dose at 1- to 2-week intervals up to 50 mg 3 times daily; add thiazide diuretic, unless severe renal impairment coexists then consider loop diuretic before further dosage increases or consider other treatment options; maximum dose: 150 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual dose range (JNC 7): 25-100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      LV dysfunction following MI:",
"     </b>",
"     Oral: Initial: 6.25 mg; if tolerated, follow with 12.5 mg 3 times daily; then increase to 25 mg 3 times daily during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times daily (some dose schedules are more aggressive to achieve an increased goal dose within the first few days of initiation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Diabetic nephropathy:",
"     </b>",
"     Oral: Initial: 25 mg 3 times daily; may be taken with other antihypertensive therapy if required to further lower blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children and Adolescents: The following adjustments have been recommended (Aronoff, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on doses of 0.1-0.5 mg/kg/dose every 6-8 hours; maximum daily dose: 6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 10-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's labeling: Reduce initial daily dose and titrate slowly (1- to 2-week intervals) with smaller increments. Slowly back titrate to determine the minimum effective dose once the desired therapeutic effect has been reached.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     The following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer 100% of normal dose every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of normal dose every 12-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of normal dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Peritoneal dialysis: Administer 75% of normal dose every 12-18 hours; supplemental dose is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 12.5 mg, 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach 1 hour before meals or 2 hours after meals; if crushing tablet and dissolving in water, allow adequate time for complete dissolution (&gt;10 minutes) (Bhatt, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at &le;30&deg;C (86&deg;F); protect from moisture and light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, and diabetic nephropathy (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F145421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Captopril may be confused with calcitriol, Capitrol&reg;, carvedilol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril [Great Britain] may be confused with Accupril which is a brand name for quinapril in the U.S.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril: Brand name for captopril [Great Britain], but also the brand name for enalapril [Hungary, Switzerland]; lisinopril [Malaysia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F145419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, angioedema, cardiac arrest, cerebrovascular insufficiency, chest pain, CHF, flushing, hypotension, MI, orthostatic hypotension, pallor, palpitation, Raynaud's syndrome, rhythm disturbances, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, depression, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bullous pemphigus, erythema multiforme, exfoliative dermatitis, pruritus, rash (maculopapular or urticarial), Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hyperkalemia, alkaline phosphatase increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, glossitis, pancreatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, neutropenia pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestasis, hepatic necrosis (rare), hepatitis, jaundice, hyponatremia (symptomatic), transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Asthenia, myalgia, myasthenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotic syndrome, oliguria, polyuria, proteinuria, renal failure, renal insufficiency, serum creatinine increased, worsening of renal function (may occur in patients with bilateral renal artery stenosis or hypovolemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, eosinophilic pneumonitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, dysgeusia - loss of taste or diminished perception, hypersensitivity reactions (arthralgia, eosinophilia, fever, pruritus, rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, angina, anorexia, aphthous ulcers, aplastic anemia, cholestatic jaundice, eosinophilia, erythrocyte sedimentation rate increased, exacerbations of Huntington's disease, glomerulonephritis, Guillain-Barr&eacute; syndrome, hemolytic anemia, hyperthermia, insomnia, interstitial nephritis, Kaposi's sarcoma, peptic ulcer, pericarditis, psoriasis, seizure (in premature infants), systemic lupus erythematosus, vasculitis, visual hallucinations (Doane, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to captopril, any component, or other ACE inhibitors; patients with idiopathic or hereditary angioedema or a history of angioedema with previous ACE inhibitor use",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage reduction may be necessary; avoid rapid dosage escalation which may lead to further renal impairment. Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution when initiating therapy and in volume-depleted patients; may cause symptomatic hypotension with or without syncope, usually with the first several doses; correct volume depletion prior to initiation; initiate lower doses in patients with sodium or volume depletion; close monitoring of patient is required, especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension alone is not a reason for discontinuation of future ACE inhibitor use, especially in patients with heart failure when a reduction in systolic blood pressure is a desirable observation. An observational study of 66 pediatric patients with heart failure reported hypotension in 15% of patients during therapy initiation at typical starting doses; close monitoring in an inpatient setting and low starting doses has been suggested in these patients (Momma, 2006; Orchard, 2010). Use with caution in patients with ischemic heart disease or cerebrovascular disease during therapy initiation; observe closely due to the potential consequences posed by falling blood pressure (eg, MI, stroke); fluid replacement may be required to restore blood pressure; therapy may then be resumed; discontinue therapy in patients whose hypotension recurs. Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hyperkalemia; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution, if at all, with these agents and monitor potassium closely. Concurrent use of angiotensin receptor blockers (ARBs) may increase the risk of clinically significant adverse events (eg, renal dysfunction, hyperkalemia).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Extemporaneous preparations of liquid formulations may vary; this may affect the rate and extent of absorption causing intrapatient variability regarding dosing and safety profile for the patient; use with caution and monitor closely if dosage formulations are changed (Bhatt, 2011; Mulla, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution before, during, or immediately after major surgery; cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release; use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor; in pediatric patients, an isolated dry hacking cough lasting &gt;3 weeks was reported in 7 of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier, 2000); a review of pediatric randomized-controlled ACE inhibitor trials reported a lower incidence of  3.2% (Baker-Smith, 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema can occur at any time during treatment (especially following first dose). The relative risk of angioedema with ACE inhibitors is higher within the first 30 days of use (compared to &gt;1 year of use), for Black Americans (compared to Whites), for lisinopril or enalapril (compared to captopril), and for patients previously hospitalized within 30 days (Brown, 1996). Angioedema may occur in the head, neck, extremities, or intestines; patients with angioedema of the intestines may present with abdominal pain (with or without nausea or vomiting); angioedema of the larynx, glottis, or tongue may cause airway obstruction, especially in patients with a history of airway surgery. Prolonged monitoring may be required, even in patients with swelling of only the tongue (ie, without respiratory distress) because treatment with corticosteroids and antihistamines may not be sufficient; very rare fatalities have occurred with angioedema of the larynx or tongue; appropriate treatment (eg, establishing patent airway and/or SubQ epinephrine) should be readily available for patients with angioedema of larynx, glottis, or tongue, in whom airway obstruction is likely to occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Life-threatening anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Captopril has been associated with rare but potentially fatal cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia; higher risk for development of neutropenia is associated with renal impairment; risk is further increased in patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus). Onset of neutropenia is usually within 3 months of captopril initiation; closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients; neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ACE inhibitor use has been associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs and initiate appropriate medical treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F145407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may reduce absorption of captopril by 25% to 40%. Long-term use of captopril may result in a zinc deficiency which can result in a decrease in taste perception; zinc supplements may be used. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Captopril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, BUN, serum creatinine, renal function, urine dipstick for protein, serum potassium, WBC with differential, especially during first 3 months of therapy for patients with renal impairment and/or collagen vascular disease; monitor for angioedema and anaphylactoid reactions; hypovolemia and postural hypotension when beginning therapy, adjusting dosage, and on a regular basis throughout",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antihypertensive: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Antihypertensive: 60-90 minutes; may require several weeks of therapy before full hypotensive effect is seen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Dose-related",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 60% to 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 25% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 50% metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants with CHF: 3.3 hours; range: 1.2-12.4 hours (Pereira, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.5 hours; range: 0.98-2.3 hours (Levy, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal adults (dependent upon renal and cardiac function): 1.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with CHF: 2.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anuria: 20-40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 95% excreted in urine in 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=see_link\">",
"      see \"Captopril: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol. Notify physician immediately if swelling of face, lips, tongue, or difficulty in breathing occurs; if these occur, do not take any more doses until a physician can be consulted. Notify physician if vomiting, diarrhea, excessive perspiration, dehydration, or persistent cough occurs. Do not use salt substitute (potassium-containing) without physician advice. May cause dizziness, fainting, and lightheadedness, especially in first week of therapy; sit and stand up slowly. May cause rash. Report sore throat, fever, other signs of infection, or other side effects. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F145342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral solution may be made by allowing two 50 mg tablets to dissolve in 50 mL of distilled water. Add the contents of one 500 mg sodium ascorbate injection ampul or one 500 mg ascorbic acid tablet and allow to dissolve. Add quantity of distilled water sufficient to make 100 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 56 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, \"Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 87(6):668-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/20130570/pubmed\" id=\"20130570\" target=\"_blank\">",
"        20130570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt MD, Thomas JE, and Mondal TK, \"Variation in Captopril Formulations in Pharmacies Across Canada,\"",
"      <i>",
"       Paediatr Child Health",
"      </i>",
"      , 2011, 16(4):e30-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/22468132/pubmed\" id=\"22468132\" target=\"_blank\">",
"        22468132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown NJ, Ray WA, Snowden M, et al, &ldquo;Black Americans Have an Increased Rate of Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(1):8-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/8689816 /pubmed\" id=\"8689816 \" target=\"_blank\">",
"        8689816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M, Koren G, Klein J, et al, &ldquo;Captopril Pharmacokinetics, Blood Pressure Response and Plasma Renin Activity in Normotensive Children With Renal Scarring,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1991, 16(4):185-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/1782836/pubmed\" id=\"1782836\" target=\"_blank\">",
"        1782836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirkin BL and Newman TJ, &ldquo;Efficacy and Safety of Captopril in the Treatment of Severe Childhood Hypertension: Report of the International Collaborative Study Group,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1985, 75(6):1091-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/3889818/pubmed\" id=\"3889818\" target=\"_blank\">",
"        3889818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Momma K, \"ACE Inhibitors in Pediatric Patients With Heart Failure,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2006, 8(1):55-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/16494512/pubmed\" id=\"16494512\" target=\"_blank\">",
"        16494512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mulla H, Tofeig M, Bu'Lock F, et al, \"Variations in Captopril Formulations Used to Treat Children With Heart Failure: A Survey in the United Kingdom,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2007, 92(5):409-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/17363396/pubmed\" id=\"17363396\" target=\"_blank\">",
"        17363396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orchard EA, Apps A, and Wilson N, \"Use of Captopril in Paediatric Congestive Cardiac Failure: Early Effects on Blood Pressure and Renal Function,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2010, 95(7):566-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/20530146/pubmed\" id=\"20530146\" target=\"_blank\">",
"        20530146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pereira CM, Tam YK, Collins-Nakai RL, &ldquo;The Pharmacokinetics of Captopril in Infants With Congestive Heart Failure,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1991, 13(3):209-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/1926273/pubmed\" id=\"1926273\" target=\"_blank\">",
"        1926273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Veterans Administration Cooperative Study Group on Antihypertensive Agents, \"Low-Dose Captopril for the Treatment of Mild to Moderate Hypertension. I. Results of a 14-Week Trial,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1984, 144(10):1947-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/6237623/pubmed\" id=\"6237623\" target=\"_blank\">",
"        6237623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Mozzettini S, Truttmann AC, et al, &ldquo;Cough is Common in Children Prescribed Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 2000, 84(1):98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/20/18760/abstract-text/10644922/pubmed\" id=\"10644922\" target=\"_blank\">",
"        10644922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13112 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18760=[""].join("\n");
var outline_f18_20_18760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708658\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145364\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051458\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442196\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051450\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145337\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145321\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051462\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051453\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051461\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145421\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145419\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051467\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051449\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051448\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145407\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145330\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051470\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145333\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145347\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051457\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051447\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051465\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051466\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051455\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145342\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13112\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13112|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=related_link\">",
"      Captopril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=related_link\">",
"      Captopril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_20_18761="Screening for coronary heart disease in patients with diabetes mellitus";
var content_f18_20_18761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for coronary heart disease in patients with diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Joanne D Schuijf, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Frans J Th Wackers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18761/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18761/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/20/18761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DIABETES AND CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to individuals without diabetes, those with diabetes have a higher prevalence of coronary heart disease (CHD), a greater extent of myocardial ischemia, and are more likely to have a myocardial infarction (MI) and silent myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/1\">",
"     1",
"    </a>",
"    ]. The increase in cardiovascular risk is due both to diabetes and to the frequent presence of other risk factors (eg, dyslipidemia and hypertension).",
"   </p>",
"   <p>",
"    The National Cholesterol Education Program report from the United States and guidelines from Europe consider type 2 diabetes to be a CHD equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This classification was based in part upon the observation that patients with type 2 diabetes without a prior MI (mean age 58) were at the same risk for MI (20 and 19 percent, respectively) and coronary mortality (15 versus 16 percent) as patients without diabetes who had a prior MI (mean age 56) (",
"    <a class=\"graphic graphic_figure graphicRef80251 \" href=\"UTD.htm?34/1/34845\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/4\">",
"     4",
"    </a>",
"    ]. It should be noted that this report was published before the use of current (and more aggressive) preventative therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies on cardiovascular risk in diabetes have been performed in patients with type 2 diabetes, who are typically older at disease onset than those with type 1 diabetes. A population-based retrospective cohort study of almost 10 million adults (380,000 with diabetes) in Ontario, Canada estimated that the transition to high cardiovascular risk (10 year event rate risk of greater than 20 percent) in diabetic individuals occurs at age 41 in men and 48 in women, approximately 15 years earlier than in individuals without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with type 1 diabetes are also at increased cardiovascular risk that increases rapidly after age 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations are consistent with the American Diabetes Association practice guideline, which considered the transition to high cardiovascular risk to occur above age 40 in patients with both type 2 and type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the increase in cardiovascular events, patients with type 2 diabetes also have a high rate of asymptomatic coronary artery disease compared to the general population as will be described below. Furthermore, asymptomatic patients may have coronary anatomy that does not permit optimal outcomes with percutaneous coronary intervention or coronary artery bypass graft surgery; this is most likely to occur in patients with two or more other cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations raise the possibility that there might be value from screening asymptomatic diabetic patients for CHD. Issues related to screening for CHD in patients with diabetes will be reviewed here.",
"   </p>",
"   <p>",
"    The epidemiology of CHD in patients with diabetes and the data related to screening for CHD in the general population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE OF ASYMPTOMATIC CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic CHD in patients with diabetes includes lesions that are insufficient to produce ischemia and those that can produce ischemia (eg, with exercise), but may not be appreciated by the patient. Some diabetic patients have a blunted appreciation of ischemic pain, which may result in atypical anginal symptoms, silent ischemia, or even silent infarction. Silent ischemia in diabetes is thought to be caused at least in part by autonomic denervation of the heart. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Silent ischemia and infarction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=see_link\">",
"     \"Silent myocardial ischemia: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of asymptomatic CHD in patients with diabetes has been evaluated in a variety of ways. These include assessment for coronary artery calcification, stress testing to detect silent ischemia, and coronary angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Coronary artery calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence and extent of coronary artery calcification (CAC) on electron beam CT scan can noninvasively predict the presence of coronary artery atherosclerosis. CAC scanning estimates total atherosclerotic burden, but is not necessarily predictive of significant coronary artery stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency and potential clinical importance of CAC in patients with diabetes who have no defined coronary artery disease is illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Across age groups, asymptomatic men and women with diabetes have higher median CAC scores on electron beam CT scanning than individuals without diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 510 asymptomatic patients with type 2 diabetes (mean age 53), 136 (27 percent) had moderate to severe CAC as defined by an Agatston score &gt;100 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/12\">",
"       12",
"      </a>",
"      ]. On stress radionuclide myocardial perfusion imaging, perfusion abnormalities were noted in 32 percent of patients with moderate to severe CAC and 60 percent with severe CAC (Agatston score &ge;400) most of which were reversible. In contrast, perfusion abnormalities were detected in only 15 percent of a random sample of 53 patients with a CAC score &le;100. Event-free survival varied inversely with both the extent of coronary calcium and the extent of ischemic myocardium on perfusion imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stress testing and coronary arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic patients have an increased frequency of silent ST segment depression and coronary perfusion abnormalities during stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/9,10,12-16\">",
"     9,10,12-16",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prospective Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects (DIAD) study identified silent ischemia in 22 percent of 1123 asymptomatic patients with type 2 diabetes (age 50 to 75 years) who underwent adenosine stress radionuclide myocardial perfusion imaging (rMPI) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/13\">",
"       13",
"      </a>",
"      ]. Large defects were found in six percent and ten percent of participants had small defects on rMPI.",
"      <br/>",
"      <br/>",
"      In contrast to the findings in DIAD, large retrospective series in asymptomatic diabetic patients reported higher rates of abnormal stress tests (40 to 60 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/9,17,18\">",
"       9,17,18",
"      </a>",
"      ]and of high-risk findings (approximately 20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. However, referral bias may have affected the results of these studies.",
"     </li>",
"     <li>",
"      A greater frequency of silent ischemia in diabetic patients was found in a report of 50 consecutive diabetic and 50 consecutive nondiabetic patients with ischemia on exercise thallium-201 scintigraphy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/14\">",
"       14",
"      </a>",
"      ]. Both groups had a similar extent of ischemia, but the diabetic patients were much more likely to have no chest pain at the time of ischemia (72 versus 32 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A high rate of silent ischemia was also noted in a retrospective observational study of 1899 asymptomatic patients with type 2 diabetes age &le;60 years (mean age 53) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/9\">",
"     9",
"    </a>",
"    ]. The patients underwent pharmacologic stress testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    myocardial contrast echocardiography (MCE) and follow-up coronary angiography if the MCE was abnormal. The stress test was abnormal in 60 percent, 65 percent of whom had significant coronary disease on angiography. This report also evaluated the relationship between the number of risk factors and the presence of silent ischemia. Sixty percent of patients had &ge;2 other CHD risk factors (dyslipidemia, hypertension, smoking, a positive family history of premature CHD, or the presence of microalbuminuria).",
"   </p>",
"   <p>",
"    The two risk groups (&ge;2 versus 0 or 1 risk factors) had equivalent rates of an abnormal stress test (60 percent) and of significant coronary disease on angiography (65 percent in those with positive stress tests). However, the patients with &ge;2 other risk factors had more severe coronary disease with significantly higher rates of three-vessel disease (33 versus 8 percent), diffuse disease (55 versus 18 percent), and vessel occlusion (31 versus 4 percent); they were also more likely to have coronary anatomy that might not permit successful percutaneous coronary intervention or coronary artery bypass graft surgery (42 versus 11 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another retrospective series of 1427 asymptomatic diabetic patients without known coronary disease, 212 underwent coronary angiography within six months of a stress SPECT radionuclide myocardial perfusion imaging (rMPI) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/18\">",
"       18",
"      </a>",
"      ]. High-risk coronary lesions (left main, three-vessel, proximal left anterior descending) were present in 61 percent of patients with high-risk SPECT images. Among patients with low-risk SPECT images, only 16 percent had high-risk coronary lesions and 40 percent had no significant coronary disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stress rMPI'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above observations demonstrate the apparent magnitude of CHD risk in patients with diabetes. However, there are three issues that must be addressed concerning the possible role of screening for CHD in such patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the purpose of screening?",
"     </li>",
"     <li>",
"      How could screening be accomplished?",
"     </li>",
"     <li>",
"      Does intervening for a positive test improve outcome?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Purpose of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary purpose of screening would be to identify patients whose prognosis could be improved with medical therapy or myocardial revascularization. Since diabetes is a considered a coronary equivalent as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], the results of screening will not change medical therapy since aggressive secondary prevention measures, such as control of blood pressure and lipids and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , would already be warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stress tests for diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When stress testing is performed for the diagnosis of CHD in the general population, many experts recommend standard exercise ECG testing if the resting ECG is normal, since the exercise response will be an important factor in determining prognosis. If the resting ECG has abnormalities that will interfere with interpretation during exercise or if localization of ischemia is expected to be important, an exercise test with imaging can be performed (eg, echocardiography or radionuclide myocardial perfusion imaging). For patients who cannot exercise, pharmacologic stress testing should be performed (",
"    <a class=\"graphic graphic_table graphicRef52995 graphicRef61603 \" href=\"UTD.htm?10/13/10462\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coronary angiography is the gold standard for defining coronary anatomy and has been used to assess the predictive value of functional stress testing for significant coronary stenoses (often defined as &ge;50 percent luminal diameter narrowing). However, lesser degrees of luminal narrowing may be associated with stress-inducible ischemia, which may in part reflect microvascular dysfunction, while \"significant\" stenoses are often not associated with stress-inducible ischemia. For these reasons and because of the invasive nature of the test, coronary angiography is not recommended as an initial screening test for CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How diabetes affects diagnostic stress test performance is not well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/21\">",
"     21",
"    </a>",
"    ]. Some have suggested low accuracy of exercise ECG testing in these patients. Limited data suggest that the other stress test modalities perform similarly in diabetic and nondiabetic patients. In each of the following studies, the patients were largely referred for stress testing because CHD was suspected; as a result, the findings may not apply to a screening population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Stress rMPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The test performance of exercise or adenosine stress SPECT radionuclide myocardial perfusion imaging (rMPI) was evaluated in 138 patients with diabetes and 188 patients without diabetes who had coronary angiography within six months of the stress test [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients had no prior myocardial infarction or revascularization and only 50 percent had angina symptoms.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of SPECT rMPI in the diabetic patients were 86 and 56 percent for &ge;50 percent diameter stenosis and 90 and 50 percent for &ge;70 percent diameter stenosis. Test performance was similar with exercise and adenosine and in the nondiabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The test performance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    -atropine stress echocardiography was evaluated in 50 patients with diabetes and 240 patients without diabetes, all of whom underwent coronary angiography; the patients were unable to perform an exercise stress test [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/23\">",
"     23",
"    </a>",
"    ]. The sensitivity and specificity were 81 and 85 percent, respectively, in the diabetic patients; similar values were noted in the nondiabetic patients (74 and 87 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The test performance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress myocardial contrast echocardiography was evaluated in a review of 128 diabetic patients who also underwent coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/24\">",
"     24",
"    </a>",
"    ]. The sensitivity and specificity were 89 and 52 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Noninvasive coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive coronary angiography can be performed with either CT or MRI techniques. At present, neither is an alternative to invasive, selective coronary angiography and neither is recommended for screening asymptomatic patients, including those at high risk. Furthermore, the higher rate of extensive coronary calcification in patients with diabetes interferes with the interpretation of stenosis severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Stress tests for prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive stress testing is performed for prognosis as well as diagnosis. With respect to screening for CHD, identifying patients at high risk would be an important component, since these are the patients in whom intervention might be considered. These issues in the general population of patients who undergo stress testing are discussed in detail separately but will be summarized briefly here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In terms of prognosis, patients are generally classified into three categories based upon estimated annual cardiac mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk &mdash; less than 1 percent per year",
"     </li>",
"     <li>",
"      Moderate risk &mdash; 1 to 3 percent per year",
"     </li>",
"     <li>",
"      High risk &mdash; more than 3 percent per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, as noted below, the good prognosis of a low risk test may not apply to diabetic patients after the first two years. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Low-risk stress tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following summarizes the major prognostic findings of the different stress tests.",
"   </p>",
"   <p>",
"    Exercise stress, if possible, is preferred, since the response to exercise itself has prognostic value. Bad prognostic signs include poor exercise capacity (&lt;5 METs); exercise-induced angina; abnormally low peak systolic blood pressure (&lt;130 mmHg) or a fall in the systolic blood pressure during exercise; and chronotropic incompetence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of prognostic variables have been identified during exercise ECG testing. The Duke treadmill score is one of the major methods used to estimate prognosis on exercise ECG testing. It utilizes three variables: exercise time (in minutes based on the Bruce protocol); maximum ST segment deviation in mm; and the presence or absence of exercise angina. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The main echocardiographic prognostic variable on stress echocardiography is the extent (single or multivessel territory) and severity of stress-induced left ventricular dysfunction (",
"      <a class=\"graphic graphic_figure graphicRef68442 \" href=\"UTD.htm?4/62/5102\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The main prognostic variable on stress rMPI is the number of vascular territories with perfusion defects (",
"      <a class=\"graphic graphic_figure graphicRef68509 \" href=\"UTD.htm?35/13/36062\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"       \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"       \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two additional issues that need to be addressed: the added prognostic value of combined testing; and how a low risk test may not predict a good prognosis in diabetic patients after two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Value of combined testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined testing with exercise ECG and an imaging procedure can provide more refined prognostic information. The magnitude of this interaction was illustrated in a study that evaluated outcomes according to the Duke treadmill score and exercise echocardiography in 5375 patients with known or suspected CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/25\">",
"     25",
"    </a>",
"    ]. Data were not available about the results in diabetic patients.",
"   </p>",
"   <p>",
"    At a mean follow-up of 5.5 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a low risk Duke treadmill score, the yearly mortality in those with a normal rest echo study or evidence of disease in a single or multivessel territory was 0.7, 1.8, and 3 percent, respectively. However, although multivessel territory disease on echocardiography was associated with increased risk, it was present in only 1.4 percent of patients with a low risk Duke treadmill score.",
"     </li>",
"     <li>",
"      Among patients with a moderate risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 2.4, 3.7, and 7 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a high risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 4.6, 5, and 12 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a normal echocardiographic study, the yearly mortality was 1 percent overall, and 0.7, 2.4, and 4.6 percent, respectively, in patients with a low, moderate, and high risk Duke treadmill score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Stress rMPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the prognostic value of stress rMPI in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/17,18,26-28\">",
"     17,18,26-28",
"    </a>",
"    ]. The predictive value of stress rMPI with exercise, adenosine, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    was evaluated in a study of 4755 patients with symptoms of CHD (ie, not a screening population), of whom 929 were diabetic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/26\">",
"     26",
"    </a>",
"    ]. At 2.5 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic patients had a significantly higher rate of cardiac death or MI than nondiabetic patients (8.6 versus 4.5 percent) and a higher rate of revascularization.",
"     </li>",
"     <li>",
"      An abnormal stress rMPI (71 percent exercise, 29 percent adenosine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      ) was an independent predictor of cardiac events in both diabetic and nondiabetic patients, with the highest rate of myocardial infarction (17 percent) being seen in diabetic patients with reversible defects in two or more territories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a second study that evaluated 1737 diabetic patients without known CHD who were asymptomatic, had angina-like chest pain, or had dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/17\">",
"     17",
"    </a>",
"    ]. The annual rate of cardiac death or nonfatal MI was significantly higher in patients with an abnormal stress rMPI (5.4 versus 1.9 percent). The event rates were similar in asymptomatic patients and those with angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the prognostic value of stress echocardiography in symptomatic patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/27,29-31\">",
"     27,29-31",
"    </a>",
"    ]. As with stress rMPI, there is a higher event rate in patients with an abnormal compared to a normal study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Among patients with an abnormal stress echocardiogram, the event rate is higher in those with multivessel abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 937 diabetic patients who underwent stress echocardiography (using exercise or, if unable to exercise maximally,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ) for either symptom evaluation or follow-up of known CHD (ie, not a screening population) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/29\">",
"     29",
"    </a>",
"    ], patients who were unable to exercise had worse outcomes, a finding similar to that in other studies. The mortality rate in patients with a normal test was 4 percent per year; the risk was increased in older patients and those requiring dobutamine stress.",
"   </p>",
"   <p>",
"    In a study of 2349 patients with diabetes who underwent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography, clinical (age, male sex, hypertension, insulin therapy, smoking, prior myocardial infarction) and stress echocardiographic variables (ejection fraction, failure to achieve target heart rate, percent ischemic segments) were combined to stratify patients into low, intermediate and high risk groups. The estimated five-year survivals in the three risk categories were 69, 60, and 47 percent, respectively. A similar model was developed for cardiovascular morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic value of a normal stress echocardiogram was directly addressed in a review of 233 patients (89 with diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/30\">",
"     30",
"    </a>",
"    ]. At a mean follow-up of 25 months, the patients with diabetes had a higher rate of nonfatal MI (6.7 versus 1.4 percent) and a higher annual hard event rate (6.0 versus 2.7 percent). They also had significantly higher rates of hypertension, hyperlipidemia, and a history of CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Low-risk stress tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients with a normal stress test generally have an annual mortality rate below 1 percent. The applicability of this relationship to patients with diabetes was evaluated in a study cited above of 4755 patients (929 with diabetes) with symptoms of CHD who underwent stress rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/26\">",
"     26",
"    </a>",
"    ]. In the patients with a normal stress rMPI, cardiac mortality was low and equivalent in diabetic and nondiabetic patients for the first two years. However, after two years, there was a sharp increase in cardiac events in the diabetic patients, with the highest risk in diabetic women.",
"   </p>",
"   <p>",
"    Similar findings were noted in a series of 563 patients with diabetes with known or suspected CHD (mean age 64) who underwent exercise echocardiography and were followed for up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/31\">",
"     31",
"    </a>",
"    ]. The stress test was normal in 224 (40 percent). The rate of cardiac death or nonfatal MI was 0 percent at one year but increased to 1.8 percent at three years and 7.6 percent at five years.",
"   </p>",
"   <p>",
"    The worse outcomes in patients with diabetes could reflect more rapid progression of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/33\">",
"     33",
"    </a>",
"    ]. Such observations have led to the suggestion that the \"warranty period\" of a normal stress rMPI may be limited in high-risk patients (such as those with diabetes), and that repeat testing after two years may be required in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     CAC scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coronary artery calcium (CAC) score adds independent prognostic information in asymptomatic individuals to that determined by the Framingham risk score. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\", section on 'Effect on prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data specific to diabetic patients are limited. A large, observational study evaluated 10,377 asymptomatic individuals, including 903 with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/35\">",
"     35",
"    </a>",
"    ]. At an average follow-up of five years, the CAC score predicted all-cause mortality in both diabetic and nondiabetic individuals. There was a highly significant interaction between the CAC score and diabetes, with a greater increase in mortality for every increase in CAC score in the diabetic patients. However, in patients without coronary artery calcium, survival at five years was similar in those with and without diabetes.",
"   </p>",
"   <p>",
"    The results were different in a smaller study of 1312 high-risk individuals (269 with diabetes), which did not find an incremental value of the CAC score in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/36\">",
"     36",
"    </a>",
"    ]. The discrepant findings may be related to differences in sample size and risk profile [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/37\">",
"     37",
"    </a>",
"    ]. Further studies are indicated.",
"   </p>",
"   <p>",
"    It has been suggested that CAC screening could be an initial screening approach, with diabetic patients with severe atherosclerosis (CAC score &gt;400) being referred for stress testing with SPECT or echocardiographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/38\">",
"     38",
"    </a>",
"    ]. However, such an approach cannot be recommended without some evidence that outcomes are improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Does screening improve outcomes?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality, prospective data showing that intervention in asymptomatic diabetic patients with high-risk findings on stress testing improves outcomes.",
"   </p>",
"   <p>",
"    In addition there are no strong data to support a benefit of screening asymptomatic patients with type 2 diabetes for silent myocardial ischemia. While findings in a retrospective observational study and a small, open-label randomized trial suggested possible benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], the large Detection of Ischemia in Asymptomatic Diabetics (DIAD) trial found no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DIAD randomly assigned 1123 asymptomatic patients with type 2 diabetes to screening for myocardial ischemia with adenosine-stress radionuclide myocardial perfusion imaging or no screening. All patients received aggressive preventative therapies. The results of the stress imaging studies were reported to the participants and their clinicians, and the information could be used as deemed appropriate. The primary end point was the combination of cardiac death or nonfatal myocardial infarction.",
"   </p>",
"   <p>",
"    At a mean follow-up of 4.8 years the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of silent ischemia in the screened group was only 22 percent. Of those with positive stress imaging results most had mild screening abnormalities and high-risk results occurred in only six percent.",
"     </li>",
"     <li>",
"      Stress tests for clinical reasons were performed in 30 percent of patients in the no-screening group. Comparable to the group with screening, about 25 percent of these non-protocol tests were abnormal.",
"     </li>",
"     <li>",
"      The cumulative cardiac event rate for all patients was 2.9 percent, which was lower than expected.",
"     </li>",
"     <li>",
"      There was no significant difference in the primary end point between the screening and no-screening groups (2.7 versus 3.0 percent respectively).",
"     </li>",
"     <li>",
"      Coronary artery revascularization was infrequently performed and was not statistically different between the screening and no-screening groups (5.5 versus 7.8 percent respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As pointed out by the authors, patients with suboptimal glucose control, untreated traditional risk factors and symptoms of chest discomfort are not comparable to the DIAD patients and require a different clinical approach and a low threshold for diagnostic testing. Similarly, patients with upcoming non-cardiac surgery or those with symptomatic peripheral artery disease were not studied in DIAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above findings highlight the major features of CHD risk in patients with diabetes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The transition to high cardiovascular risk (10 year event rate risk of greater than 20 percent) occurs at age 40 to 45 in patients with type 2 and age 30 in patients with type 1 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diabetic patients have a high rate of asymptomatic CHD, which can be detected by computed tomography (using calcium scoring or non-invasive angiography to detect coronary atherosclerosis) or stress testing (to detect ischemia). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence of asymptomatic CHD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Stress tests for diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic patients with a positive stress test have an increased risk of mortality and nonfatal MI that is proportional to the severity and extent of abnormalities on the stress test. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Stress tests for prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initially good prognosis of a low risk test in diabetic patients with known or suspected CHD may not apply after the first two years. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Low-risk stress tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a study of 1899 asymptomatic patients with type 2 diabetes who were &le;60 years of age (mean age 53), those who had two or more other cardiovascular risk factors (dyslipidemia, hypertension, smoking, a positive family history of premature CHD, or the presence of microalbuminuria) had an increased risk (compared to diabetics with no or one risk factor) of three-vessel disease, diffuse coronary disease, or complete occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/9\">",
"       9",
"      </a>",
"      ]. These patients were also more likely to have coronary anatomy that might not permit successful percutaneous coronary intervention or coronary artery bypass graft surgery (42 versus 11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Criteria for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Such observations have provided a rationale for screening asymptomatic diabetic patients with CHD that has been widely debated in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/19,27,38,42\">",
"     19,27,38,42",
"    </a>",
"    ]. It has been suggested that the following criteria should be met before screening can be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of CHD should be sufficiently high. In large retrospective series, abnormal stress tests have been reported in 40 to 60 percent of patients in large retrospective series and approximately 20 percent had high-risk findings [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/9,17-19\">",
"       9,17-19",
"      </a>",
"      ]. The only prospective study (DIAD) reported much lower rates of abnormal stress rMPI (22 percent) and high-risk findings (large defects were present in 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Does screening improve outcomes?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The screening test should accurately differentiate low and high risk patients. High-risk patients can be identified. However, low-risk stress tests appear to predict low risk for only two years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/18,26,31\">",
"       18,26,31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Stress tests for prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Low-risk stress tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification of patients at risk should lead to treatment with better outcomes. As noted above, identification of silent ischemia will not change medical therapy, since aggressive secondary prevention measures, such as control of blood pressure and lipids and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , would already be warranted. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Purpose of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The screening strategy must be cost-effective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most cost effective approach to screening and prevention of cardiovascular events in asymptomatic patients with diabetes remains a subject of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of screening for CHD in patients with diabetes has been addressed by the American Diabetes Association (ADA) and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA):",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      American Diabetes Association does not recommend routine screening for CHD in patients with diabetes as screening has not been shown to improve outcomes compared with aggressively treating risk factors alone [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/8\">",
"       8",
"      </a>",
"      ]. However, some high risk patients may be candidates for screening with stress testing if there is a history of peripheral or carotid arterial disease.",
"      <br/>",
"      <br/>",
"      The ADA guidelines recommend annual assessment of risk criteria to identify patients who might benefit from interventions such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , ACE inhibitors, or statins, but no longer recommend that these criteria be used to identify patients for stress testing [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An ADA consensus statement indicated that new imaging techniques for early detection of CHD have become available (calcium scoring and noninvasive coronary angiography with computed tomography), but, at the same time, diabetes has been recognized as a cardiovascular disease equivalent, which already warrants optimized medical therapy, and screening for atherosclerosis will not alter treatment. It remains to be demonstrated whether treatment of ischemia (by coronary revascularization) will alter prognosis; if this occurs to be the case, then screening for ischemia may be warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2002",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines for exercise testing made a more limited conclusion that the weight of evidence favors evaluation only in asymptomatic patients with diabetes who plan to begin a vigorous exercise program [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18761/abstract/45\">",
"       45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Evidence of improved outcomes is required before screening in other asymptomatic diabetic patients can be recommended. If stress testing is performed, we suggest either rMPI or echocardiography with ECG monitoring. Exercise stress is preferred because the response to exercise itself has prognostic value. If the patient cannot adequately exercise, pharmacologic stress is warranted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1076895203\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Don Poldermans, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/1\">",
"      Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000; 36:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/2\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/3\">",
"      De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/4\">",
"      Haffner SM, Lehto S, R&ouml;nnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/5\">",
"      Bax JJ, Young LH, Frye RL, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007; 30:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/6\">",
"      Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/7\">",
"      Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/8\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/9\">",
"      Scognamiglio R, Negut C, Ramondo A, et al. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/10\">",
"      Hoff JA, Quinn L, Sevrukov A, et al. The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. J Am Coll Cardiol 2003; 41:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/11\">",
"      Schurgin S, Rich S, Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 2001; 24:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/12\">",
"      Anand DV, Lim E, Hopkins D, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 2006; 27:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/13\">",
"      Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/14\">",
"      Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988; 108:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/15\">",
"      Nesto RW, Watson FS, Kowalchuk GJ, et al. Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: assessment by dipyridamole thallium-201 scintigraphy. Am Heart J 1990; 120:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/16\">",
"      Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Am J Cardiol 1997; 79:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/17\">",
"      Zellweger MJ, Hachamovitch R, Kang X, et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J 2004; 25:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/18\">",
"      Rajagopalan N, Miller TD, Hodge DO, et al. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol 2005; 45:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/19\">",
"      Miller TD, Redberg RF, Wackers FJ. Screening asymptomatic diabetic patients for coronary artery disease: why not? J Am Coll Cardiol 2006; 48:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/20\">",
"      Nitenberg A, Valensi P, Sachs R, et al. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993; 42:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/21\">",
"      Heller GV. Evaluation of the patient with diabetes mellitus and suspected coronary artery disease. Am J Med 2005; 118 Suppl 2:9S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/22\">",
"      Kang X, Berman DS, Lewin H, et al. Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J 1999; 137:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/23\">",
"      Elhendy A, van Domburg RT, Poldermans D, et al. Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test. Diabetes Care 1998; 21:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/24\">",
"      Elhendy A, Tsutsui JM, O'Leary EL, et al. Noninvasive diagnosis of coronary artery disease in patients with diabetes by dobutamine stress real-time myocardial contrast perfusion imaging. Diabetes Care 2005; 28:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/25\">",
"      Marwick TH, Case C, Vasey C, et al. Prediction of mortality by exercise echocardiography: a strategy for combination with the duke treadmill score. Circulation 2001; 103:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/26\">",
"      Giri S, Shaw LJ, Murthy DR, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 2002; 105:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/27\">",
"      Anand DV, Lim E, Lahiri A, Bax JJ. The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects. Eur Heart J 2006; 27:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/28\">",
"      Kang X, Berman DS, Lewin HC, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J 1999; 138:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/29\">",
"      Marwick TH, Case C, Sawada S, et al. Use of stress echocardiography to predict mortality in patients with diabetes and known or suspected coronary artery disease. Diabetes Care 2002; 25:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/30\">",
"      Kamalesh M, Matorin R, Sawada S. Prognostic value of a negative stress echocardiographic study in diabetic patients. Am Heart J 2002; 143:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/31\">",
"      Elhendy A, Arruda AM, Mahoney DW, Pellikka PA. Prognostic stratification of diabetic patients by exercise echocardiography. J Am Coll Cardiol 2001; 37:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/32\">",
"      Chaowalit N, Arruda AL, McCully RB, et al. Dobutamine stress echocardiography in patients with diabetes mellitus: enhanced prognostic prediction using a simple risk score. J Am Coll Cardiol 2006; 47:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/33\">",
"      Wackers FJ, Zaret BL. Detection of myocardial ischemia in patients with diabetes mellitus. Circulation 2002; 105:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/34\">",
"      Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? J Am Coll Cardiol 2003; 41:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/35\">",
"      Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004; 43:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/36\">",
"      Qu W, Le TT, Azen SP, et al. Value of coronary artery calcium scanning by computed tomography for predicting coronary heart disease in diabetic subjects. Diabetes Care 2003; 26:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/37\">",
"      Raggi P, Bellasi A, Ratti C. Ischemia imaging and plaque imaging in diabetes: complementary tools to improve cardiovascular risk management. Diabetes Care 2005; 28:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/38\">",
"      Scholte AJ, Bax JJ, Wackers FJ. Screening of asymptomatic patients with type 2 diabetes mellitus for silent coronary artery disease: combined use of stress myocardial perfusion imaging and coronary calcium scoring. J Nucl Cardiol 2006; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/39\">",
"      Sorajja P, Chareonthaitawee P, Rajagopalan N, et al. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation 2005; 112:I311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/40\">",
"      Faglia E, Manuela M, Antonella Q, et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J 2005; 149:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/41\">",
"      Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/42\">",
"      Bax JJ, Bonow RO, Tsch&ouml;pe D, et al. The potential of myocardial perfusion scintigraphy for risk stratification of asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 2006; 48:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/43\">",
"      Diamond GA, Kaul S, Shah PK. Screen testing cardiovascular prevention in asymptomatic diabetic patients. J Am Coll Cardiol 2007; 49:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/44\">",
"      Beller GA. Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: is it appropriate and cost-effective? J Am Coll Cardiol 2007; 49:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18761/abstract/45\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40:1531.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1551 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18761=[""].join("\n");
var outline_f18_20_18761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DIABETES AND CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE OF ASYMPTOMATIC CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Coronary artery calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stress testing and coronary arteriography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Purpose of screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stress tests for diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Stress rMPI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Noninvasive coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Stress tests for prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Value of combined testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Stress rMPI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Low-risk stress tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CAC scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Does screening improve outcomes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Criteria for screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1076895203\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1551|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/1/34845\" title=\"figure 1\">",
"      Diabetes increases coronary mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5102\" title=\"figure 2\">",
"      Stress echocardiography outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/13/36062\" title=\"figure 3\">",
"      Exercise thallium predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/42/18093\" title=\"table 1A\">",
"      ACC AHA choice imaging CHD diagnosis able to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/22/21868\" title=\"table 1B\">",
"      ACC AHA choice imaging CHD diagnosis unable to exercise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=related_link\">",
"      Silent myocardial ischemia: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_20_18762="Delivery of inhaled medication in adults";
var content_f18_20_18762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Delivery of inhaled medication in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18762/contributors\">",
"     Dean Hess, RRT, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18762/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/20/18762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/20/18762/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/20/18762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delivery of therapeutic aerosols is an important component of treatment for many respiratory disorders. The advantages of aerosolized therapy include delivery of medication directly to the site of action, potentially faster onset of action, and reduced systemic availability to minimize adverse effects of the medication.",
"   </p>",
"   <p>",
"    The types and function of devices available for delivery of therapeutic aerosols are reviewed here. The education of patients regarding optimal inhaler technique and the role of these medications in the management of asthma and COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three principal types of devices used to generate therapeutic aerosols are pressurized metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/1\">",
"     1",
"    </a>",
"    ]. Nebulizer systems are typically less portable than MDIs and DPIs. In the past, nebulizers were considered more expensive delivery devices; however, in some settings, brand name HFA formulations of MDIs may be more expensive than the solutions used in a nebulizer. Among nebulizers, three basic types have been developed, jet (also known as pneumatic), ultrasonic, and mesh.",
"   </p>",
"   <p>",
"    Inhalation (or aerosol) therapy can be employed with a range of medications and devices. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled beta agonist and anticholinergic bronchodilators for chronic obstructive lung diseases (eg, asthma, COPD, bronchiectasis, bronchiolitis)",
"     </li>",
"     <li>",
"      Inhaled glucocorticoids for asthma, eosinophilic bronchitis, and COPD",
"     </li>",
"     <li>",
"      Inhaled antibiotics for prevention of Pneumocystis pneumonia and treatment of respiratory syncytial virus, cystic fibrosis, and bronchiectasis",
"     </li>",
"     <li>",
"      Airway secretion modifying agents for cystic fibrosis",
"     </li>",
"     <li>",
"      Inhaled pulmonary vasodilators for pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aerosol delivery of drugs (eg, opiates) may be used to treat some nonrespiratory diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages and disadvantages to each of the different types of aerosol delivery devices are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef71527 \" href=\"UTD.htm?17/10/17581\">",
"     table 1",
"    </a>",
"    ). The available evidence from systematic reviews and meta-analyses suggests equivalence among nebulizers, MDIs, and DPIs for delivery of beta agonists and glucocorticoids when used correctly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. Thus, for spontaneously breathing patients without a tracheostomy, the selection of an aerosol delivery device is usually based upon the preference and convenience of the clinician and patient, the ability of the patient to use the device correctly, and the cost of therapy rather than a clear superiority of one device over another [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in a few select situations, choice of device is determined by drug formulation, as some formulations require a particular delivery device, and patient interface factors, such as presence of a tracheotomy or mechanical ventilation.",
"   </p>",
"   <p>",
"    The proper technique for using aerosol devices varies from one device to another and is a key component of optimal drug deposition and the desired therapeutic response. Understanding the correct use of aerosol delivery devices and providing patient education is a shared responsibility among all health care professionals participating in asthma or COPD management (eg, physicians, respiratory therapists, nurses, and pharmacists) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/14\">",
"     14",
"    </a>",
"    ]. Inhaler technique for MDIs and DPIs is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All three types of devices can be used to deliver medication to spontaneously breathing patients who can inhale orally. Only nebulizers and MDIs can be used in patients who are intubated or have a tracheostomy; DPIs are not designed for use in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339815\">",
"    <span class=\"h1\">",
"     METERED DOSE INHALERS (MDI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An MDI consists of a pressurized canister, a metering valve and stem, and a mouthpiece actuator (",
"    <a class=\"graphic graphic_picture graphicRef62613 \" href=\"UTD.htm?37/43/38591\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/15\">",
"     15",
"    </a>",
"    ]. The canister contains the drug suspended in a mixture of propellants, surfactants, preservatives, flavoring agents, and dispersal agents. In the past, the propellant was a chlorofluorocarbon (CFC) but this is being replaced by hydrofluoroalkane (HFA). The mixture is released from the MDI canister through the metering valve and stem into an actuator boot. Lung deposition ranges between 10 and 40 percent of the nominal dose in adults and is very technique-dependent. The MDI can be used with a spacer or valved holding chambers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link&amp;anchor=H85082029#H85082029\">",
"     \"The use of inhaler devices in adults\", section on 'Metered dose inhalers with CFC and HFA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of medications available in an MDI include short and long-acting beta agonists (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 2",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    , and a number of inhaled glucocorticoids alone and in combination with a long-acting beta-agonist (",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 4",
"    </a>",
"    ). The correct techniques for using an MDI, determining when the canister is empty, and deciding when to use a spacer or chamber device are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"     \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339674\">",
"    <span class=\"h1\">",
"     DRY POWDER INHALERS (DPI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry powder inhalers (DPIs) create medication aerosols by drawing air through a dose of powdered medication (",
"    <a class=\"graphic graphic_picture graphicRef57922 \" href=\"UTD.htm?41/43/42675\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. They produce aerosols in which most of the drug particles are in the respirable range; however, the distribution of particle sizes differs significantly among the various DPIs. These devices are either single-dose or multiple-dose. The single dose devices require the patient or caregiver to load a capsule of drug with each treatment, whereas the multiple dose devices typically contain a month&rsquo;s supply of drug.",
"   </p>",
"   <p>",
"    High ambient humidity produces clumping of the powder, creating larger particles that are not as effectively aerosolized. DPI devices that use individually packaged capsules protect the powder from humidity and limit this effect. The effect of humidity and the need for a tight seal for breath actuation makes all DPIs",
"    <strong>",
"     ineffective",
"    </strong>",
"    for use in patients with a tracheostomy or endotracheal tube.",
"   </p>",
"   <p>",
"    Examples of medications available in a DPI include several inhaled glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 4",
"    </a>",
"    ), long-acting beta agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/59/26549?source=see_link\">",
"     indacaterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 2",
"    </a>",
"    ), and the inhaled anticholinergic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    . The use of DPI devices is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link&amp;anchor=H3503338#H3503338\">",
"     \"The use of inhaler devices in adults\", section on 'DPI technique'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H13#H13\">",
"     \"The use of inhaler devices in children\", section on 'Dry powder inhalers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEBULIZERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three basic types of nebulizer devices are jet (also known as pneumatic), ultrasonic, and mesh. Nebulizer performance is affected by both technical and patient-related factors (",
"    <a class=\"graphic graphic_table graphicRef58515 \" href=\"UTD.htm?32/24/33163\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339203\">",
"    <span class=\"h2\">",
"     Jet nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic design of jet (pneumatic) nebulizers has changed little over the past 25 years (",
"    <a class=\"graphic graphic_figure graphicRef57284 \" href=\"UTD.htm?33/44/34496\">",
"     figure 1",
"    </a>",
"    ). Jet nebulizers are often considered interchangeable. However, differences in performance among nebulizers produced by various manufacturers have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Some nebulizers deliver the dose of medication in a shorter time, while others deliver a more accurate dose or have less drug wastage. These differences may not be important for delivery of inhaled bronchodilators, but may be significant for more expensive medication formulations where precise dosing is required. (See",
"    <a class=\"local\" href=\"#H24790161\">",
"     'Nebulizers for specific medications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Enhanced nebulizer designs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339577\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operation of a jet nebulizer requires an air compressor or a pressurized gas supply (eg, compressed air, oxygen), which acts as the driving force for liquid atomization. Compressed gas is delivered as a jet through a small orifice, generating a region of negative pressure above the medication reservoir. The solution to be aerosolized is first entrained, or pulled into the gas stream (Venturi effect), and then sheared into a liquid film. This film is unstable, and rapidly breaks into droplets due to surface tension forces.",
"   </p>",
"   <p>",
"    A baffle placed in the aerosol stream allows formation of smaller droplets and recycling of larger droplets into the liquid reservoir. The aerosol of respirable particles is entrained into the inspiratory gas stream inhaled by the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10616854\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correct technique for use of a nebulizer is described in the table (",
"    <a class=\"graphic graphic_table graphicRef71696 \" href=\"UTD.htm?14/37/14939\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20150710\">",
"    <span class=\"h3\">",
"     Factors affecting drug delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors determine the efficiency of a nebulizer system, including the respirable dose, nebulization time, dead volume of the device, and the gas used to drive the nebulizer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respirable dose &ndash; The most important characteristic of nebulizer performance is the respirable dose delivered to the patient. The respirable dose is a function of the mass output of the nebulizer and the size of the droplets produced. Droplet size is usually reported as mass median aerodynamic diameter (MMAD), which is the median diameter around which the mass of the aerosol is equally divided. Droplet size should be 2 to 5 &micro;m for airway deposition (eg, bronchodilator administration) and 1 to 2 &micro;m or smaller for parenchymal deposition (eg, drugs intended for absorption into the bloodstream such as pulmonary vasodilators).",
"     </li>",
"     <li>",
"      Nebulization time &ndash; Nebulization time, the time required to deliver a dose of medication, is determined by the volume of drug to be delivered and the flow of the driving gas into the nebulizer. The larger the volume and the lower the flow, the longer the nebulization time. Nebulization time is an important determinant of patient compliance with completing a full dose in the outpatient setting. In addition, a reduction in nebulization time may decrease the need for clinical supervision in hospitalized or emergently-treated patients.",
"      <br/>",
"      <br/>",
"      During nebulization, the solution within the nebulizer becomes increasingly concentrated as water evaporates from the solution. Thus, on a per breath basis, more medication is delivered late in the course of a treatment. Patients should be encouraged to continue the treatment until there is no further pooling of medication in the bottom of the reservoir; reservoir sputtering is a good sign that the treatment is complete. Continuing treatment after sputtering is of limited value.",
"     </li>",
"     <li>",
"      Dead volume &ndash; The volume of medication trapped inside the nebulizer, and therefore not available for inhalation, is referred to as the dead volume of the device. The dead volume is typically in the range of 1 to 3 mL. Increasing the amount of solution within the nebulizer (the fill volume) reduces the proportion of the dose lost as dead volume. Although nebulizer output increases with a greater fill volume, this also results in an increase in nebulization time. Considering both factors, an initial nebulizer fill volume of 3 to 6 mL is typically used [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/22\">",
"       22",
"      </a>",
"      ]. The maximum fill volume of the nebulizer is manufacturer-determined; most do not exceed 5 mL, but some accept a volume as great as 10 mL. Unit dose ampules of bronchodilators (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      ) are typically 2.5 to 3 mL, which may not be ideal in terms of the proportion of dead volume to the total dose. However, the value of adding additional diluent to minimize the dead volume effect has not been studied.",
"      <br/>",
"      <br/>",
"      Unit dose ampules of antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ) are 5 mL, which may be more suitable to minimize the dead volume effect. When combining drug solutions in the nebulizer to minimize the time required for treatment, it is important to avoid a drug volume that exceeds the labeled maximum volume of the nebulizer and to avoid any incompatibility issues of the drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Driving gas &ndash; Increasing the flow of the driving gas results in an increase in nebulized output and a reduction in particle size. A flow of 6 to 8",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      is usually selected to optimize drug delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/22,25\">",
"       22,25",
"      </a>",
"      ]. When a compressor is used to power the nebulizer, instead of compressed air or oxygen from a wall device, the selected compressor should provide an adequate flow rate for drug aerosolization and delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/26-28\">",
"       26-28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gas density &ndash; The density of the gas powering the nebulizer affects nebulizer performance. For example, the inhaled mass of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      is significantly reduced when a nebulizer is powered with a mixture of helium and oxygen (heliox). Accordingly, in the rare situation that the nebulizer is powered with heliox, the flow to the nebulizer is increased by 50 percent to 9 to 12",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/29\">",
"       29",
"      </a>",
"      ]. Heliox may improve aerosol delivery to the lower respiratory tract, because the decrease in density results in the creation of smaller particles; however, the clinical benefit of this approach is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/30-35\">",
"       30-35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link\">",
"       \"Physiology and clinical use of heliox\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Breathing pattern &ndash; The breathing pattern of the patient affects the amount of aerosol deposited in the lower respiratory tract. Airflow obstruction increases the need for inhaled bronchodilator therapy, but can decrease the effectiveness of that treatment. To improve aerosol penetration and deposition in the lungs, the patient should be encouraged to use a slow breathing pattern with a normal tidal volume and an occasional deep breath [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10617078\">",
"    <span class=\"h3\">",
"     Continuous nebulization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with acute exacerbations of asthma, nebulized bronchodilators can be administered continuously, rather than intermittently at scheduled intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H340028\">",
"     'Acute asthma exacerbation'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    One problem with continuous nebulization is the need for refilling the standard, small volume nebulizer every 10 to 15 minutes. Strategies to avoid frequent refilling of the nebulizer chamber for continuous nebulization include use of an infusion pump connected to the nebulizer (",
"    <a class=\"graphic graphic_figure graphicRef77544 \" href=\"UTD.htm?36/63/37886\">",
"     figure 2",
"    </a>",
"    ) and use of a large volume nebulizer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/19,36\">",
"     19,36",
"    </a>",
"    ]. The usual dose for continuous nebulization of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    is 10 to 15",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"    In general, drug delivery over time by continuous nebulization appears similar to that with frequent intermittent nebulization, although some large volume nebulizers may not provide as consistent a flow rate as a small volume nebulizer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Examples of large volume nebulizers include the HEART Nebulizer (Vortran Medical) and the AirLife Misty Finity (Cardinal Health), Flo-Mist (Smith's Medical), and Hope (B&amp;B Medical Technologies) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/39\">",
"     39",
"    </a>",
"    ]. The driving gas flow for these large volume nebulizers should follow the manufacturers&rsquo; specifications.",
"   </p>",
"   <p>",
"    <br/>",
"    An issue with the use of large volume nebulizers is reconcentration of drug over time, which may necessitate changing the nebulizer or drug solution after five hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/39\">",
"     39",
"    </a>",
"    ]. Increasingly common is the use of a mesh nebulizer with an infusion pump for continuous aerosol treatment (",
"    <a class=\"graphic graphic_figure graphicRef61793 \" href=\"UTD.htm?34/6/34927\">",
"     figure 3",
"    </a>",
"    ). This can be used with a facemask or inline with a ventilator. Such a set-up is used not only for continuous aerosol bronchodilator delivery for acute asthma, but also for continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    inhalation for selective pulmonary vasodilation in critically ill patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339423\">",
"    <span class=\"h2\">",
"     Mesh nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several manufacturers have developed aerosol devices that use a mesh or plate with multiple apertures to produce a liquid aerosol (",
"    <a class=\"graphic graphic_figure graphicRef69736 \" href=\"UTD.htm?37/3/37951\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/40\">",
"     40",
"    </a>",
"    ]. The solution or suspension of medication is forced through the mesh to produce an aerosol, without need for an internal baffling system or compressed air source [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/41\">",
"     41",
"    </a>",
"    ]. A common feature of these devices is their ability to generate aerosols with a high fine-particle fraction, which results in more efficient drug delivery compared to conventional nebulizers.",
"   </p>",
"   <p>",
"    Examples of mesh nebulizers include the eFlow (Pari), Aeroneb Solo and Aeroneb Go (Aerogen),",
"    <span class=\"nowrap\">",
"     MicroAIR/NE-U22",
"    </span>",
"    (OMRON), and the I-neb (Respironics) (",
"    <a class=\"graphic graphic_picture graphicRef87397 \" href=\"UTD.htm?3/62/4079\">",
"     picture 3",
"    </a>",
"    ). These nebulizers are portable, battery-operated, and have minimal residual medication volume [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/40\">",
"     40",
"    </a>",
"    ]. Another advantage to mesh technology is the ability to deliver expensive formulations with precise dosing and minimal wastage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/42\">",
"     42",
"    </a>",
"    ] such as the Altera Nebulizer System for administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , which utilizes the eFlow nebulizer.",
"   </p>",
"   <p>",
"    The I-neb nebulizer uses mesh technology combined with Adaptive Aerosol Delivery (ADD). ADD monitors the patient's breathing pattern and injects a programable dose of the aerosol at the beginning of inhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/43\">",
"     43",
"    </a>",
"    ]. This improves the likelihood of the aerosol penetrating deep into the respiratory tract. This nebulizer is used specifically for the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    (Ventavis) inhalation solution for the treatment of pulmonary arterial hypertension (",
"    <a class=\"graphic graphic_figure graphicRef79862 \" href=\"UTD.htm?22/56/23439\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Iloprost'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, mesh nebulizers are more light-weight and portable than jet nebulizers. Mesh nebulizers usually deliver the medication dose more quickly than jet nebulizers. However, the speed of medication delivery is influenced by the position of the nebulizer. Under laboratory conditions, the Omron vibrating mesh nebulizer has a comparable drug delivery to a conventional jet nebulizer only when the Omron is in a vertical position [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/44\">",
"     44",
"    </a>",
"    ]. The time to deliver the same dose is three times longer when the Omron is in the horizontal rather than vertical position.",
"   </p>",
"   <p>",
"    Mesh nebulizers require meticulous attention to cleaning so that performance is not impaired. Manufacturer&rsquo;s recommendations should be followed for cleaning the device, which is required after each treatment, and more extensive disinfection or sterilization on a regular basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339430\">",
"    <span class=\"h2\">",
"     Ultrasonic nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonic nebulizers consist of a power unit and transducer, with or without an electric fan [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/19,45\">",
"     19,45",
"    </a>",
"    ]. The power unit converts electrical energy to high-frequency ultrasonic waves. A piezoelectric element in the transducer vibrates at the same frequency as the applied wave. Ultrasonic waves are transmitted to the surface of the solution to create an aerosol. The droplets produced by these devices have a slightly higher mass median aerodynamic diameter (MMAD) than droplets from a jet nebulizer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/46\">",
"     46",
"    </a>",
"    ]. A fan is used to deliver the aerosol to the patient, or the aerosol is evacuated from the nebulization chamber by the inspiratory flow of the patient.",
"   </p>",
"   <p>",
"    Small volume ultrasonic nebulizers (eg, Beetle Neb, Lumiscope, Minibreeze) are commercially available for delivery of bronchodilators. Advantages of ultrasonic nebulization are quieter medication delivery and shorter treatment time than the jet nebulizers. Reported problems include poor battery life and overheating. A potential issue with the use of ultrasonic nebulizers is drug inactivation by ultrasonic waves, which is the reason that ultrasonic nebulizers cannot be used to deliver medications in suspension, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    . Drug inactivation has not been shown to occur with the medications in solution that are commonly delivered using this system (eg, bronchodilators).",
"   </p>",
"   <p>",
"    The Optineb is an ultrasonic nebulizer used to deliver",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    inhalation solution for the treatment of pulmonary hypertension. The device is specific for the delivery of treprostinil and prompts the patient to use correct inhalation technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Enhanced nebulizer designs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer technologies for nebulizer design address issues of medication conservation, speed of delivery of medication, portability, battery power, and administration of specialized medications. With the traditional nebulizer design, an aerosol is generated throughout the patient's respiratory cycle. This results in considerable waste of aerosol during exhalation. Newer designs reduce aerosol waste during the exhalation phase (",
"    <a class=\"graphic graphic_picture graphicRef56942 \" href=\"UTD.htm?2/45/2770\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breath-enhanced nebulizers, such as the Pari LC, are designed to allow release of more aerosolized medication during inhalation than exhalation. With this design, exhaled gas is routed out the expiratory valve in the mouthpiece and aerosol is contained in the nebulizer chamber during the expiratory phase.",
"     </li>",
"     <li>",
"      The Circulaire and AeroTee nebulizers reduce waste from a constant-output nebulizer by attachment of a storage bag with a one-way valve in the mouthpiece connector. During the expiratory phase, aerosol is collected in the bag and delivered to the patient on the subsequent inhalation.",
"     </li>",
"     <li>",
"      The AeroEclipse nebulizer has a breath-actuated valve that triggers aerosol generation only during inhalation, eliminating the need for a storage bag or reservoir [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/47\">",
"       47",
"      </a>",
"      ]. A randomized controlled trial has reported benefit for the use of this nebulizer compared to a jet nebulizer in a pediatric emergency department setting [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339955\">",
"    <span class=\"h2\">",
"     Mouthpieces and facemasks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled aerosols from nebulizers can be administered using a mouthpiece or a facemask, although the mouthpiece interface is generally preferred.",
"   </p>",
"   <p>",
"    Bronchodilator response appears similar with either interface, and some have argued that the selection of patient interface should be based upon patient preference. Significant facial and eye deposition of aerosol can occur when a face mask is used, especially in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/49\">",
"     49",
"    </a>",
"    ]. Eye deposition is of particular concern when aerosolized anticholinergic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    ) are administered, as this can result in blurring of vision, pupil dilation, and worsening of narrow angle glaucoma. When a facemask is used, it is important to instruct the patient to inhale through the mouth to minimize nasopharyngeal deposition of medication.",
"   </p>",
"   <p>",
"    Preliminary studies suggest that aerosol medication can be delivered by nasal cannula, which may improve patient adherence for continuous aerosol delivery of bronchodilators or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, additional study of the efficacy of using nasal cannula as an interface is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339088\">",
"    <span class=\"h1\">",
"     AEROSOL DELIVERY IN SPECIAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24790161\">",
"    <span class=\"h2\">",
"     Nebulizers for specific medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug formulation can affect nebulizer performance, and some drug preparations are only approved for delivery with specific nebulizers (",
"    <a class=\"graphic graphic_table graphicRef83376 \" href=\"UTD.htm?10/53/11100\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Examples of medications that should be delivered",
"    <strong>",
"     only",
"    </strong>",
"    by approved nebulizer include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    suspension,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , DNase I,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    , as described below.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    is prepared as a suspension for nebulization. It can be administered via jet or mesh nebulizers, but not by an ultrasonic nebulizer. (See",
"    <a class=\"local\" href=\"#H339430\">",
"     'Ultrasonic nebulizers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     Iloprost",
"    </a>",
"    requires use of a nebulizer with an Adaptive Aerosol Delivery (AAD) system that controls the dosage of drug by use of a specialized disc and metering chambers. Two types of nebulizer are acceptable, the vibrating mesh nebulizer I-neb AAD (Respironics) and the jet nebulizer Prodose AAD (Respironics) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/43\">",
"     43",
"    </a>",
"    ]. The AAD metering chambers can deliver a pre-set volume ranging from 0.25 to 1.4 mL with a residual of about 0.1 mL. The drug is only delivered during inspiration and requires that the patient be conscious and breathing spontaneously.",
"   </p>",
"   <p>",
"    Specially constructed small-volume jet nebulizers, such as the Respirgard II, are used when it is necessary to prevent contamination of the ambient environment with the aerosolized drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/19\">",
"     19",
"    </a>",
"    ]. The Respirgard II is fitted with one-way valves and filters to minimize gross contamination of the environment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link&amp;anchor=H16#H16\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\", section on 'Aerosolized pentamidine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A specialized jet nebulizer is used to allow the safe delivery of aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , which is potentially teratogenic. The Viratek Small-Particle Aerosol Generator (SPAG-2) is designed specifically to aerosolize ribavirin. It consists of a nebulizer and drying chamber that reduces the MMAD to about 1.3 &micro;m, which optimizes drug delivery to distal airspaces. The SPAG-2 is used with a scavenging system to minimize contamination of the ambient environment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=see_link&amp;anchor=H9#H9\">",
"     \"Respiratory syncytial virus infection: Treatment\", section on 'Ribavirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhaled DNase I (Dornase alpha) is administered to patients with cystic fibrosis using the Pulmo-Aide, Pari-Proneb, Mobilaire, Porta-Neb, or Pari Baby jet nebulizer systems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H5#H5\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Inhaled DNase I (dornase alfa)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    is administered over 20 minutes using a handheld jet nebulizer (PARI-LC PLUS). It cannot be combined with other inhaled medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H17#H17\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Inhaled tobramycin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    is administered using the Altera Nebulizer System, which uses mesh nebulizer technology. (See",
"    <a class=\"local\" href=\"#H339423\">",
"     'Mesh nebulizers'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H24831257#H24831257\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Inhaled aztreonam lysine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    is delivered with the Optineb ultrasonic nebulizer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H340028\">",
"    <span class=\"h2\">",
"     Acute asthma exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two issues that arise when choosing an aerosol delivery system for bronchodilator medication during exacerbations of asthma are whether to use an MDI or a nebulizer and whether to use continuous or intermittent nebulization for hospital based treatment. These choices are typically based on the severity of the exacerbation and also clinician and patient preference (",
"    <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For patients who have an asthma exacerbation that is mild to moderate in severity (eg, mild to no dyspnea at rest and peak expiratory flow &ge;40 percent of predicted), administration of the beta 2-agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    via an MDI (2 to 6 puffs for treatment at home, 4 to 8 puffs for emergency room or hospital treatment) combined with a spacer or chamber device (eg, Aerochamber, Optichamber, Vortex) results in comparable improvements in lung function compared to nebulizer delivery, although the actual dose delivered by an MDI is much lower (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 2",
"    </a>",
"    ). Similar results with MDIs have been reported in patients with severe exacerbations, but only a small number of such patients have been studied. Generally, nebulizer treatments (every 20 minutes or continuous) are preferred for more severe asthma exacerbations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of acute exacerbations of asthma in adults\", section on 'Nebulizer versus MDI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with severe asthma exacerbations (eg, dyspnea at rest, accessory muscle use, retractions, forced expiratory volume in one second or peak expiratory flow &lt;40 percent predicted), beta agonists are often administered continuously rather than intermittently [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/14,56\">",
"     14,56",
"    </a>",
"    ]. Several studies have established the safety of this technique, even when high doses (eg, 20",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    of",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/albuterol-salbutamol-pediatric-drug-information?source=see_link\">",
"     albuterol",
"    </a>",
"    ) are used [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/19,56,57\">",
"     19,56,57",
"    </a>",
"    ]. Continuous nebulization may be most beneficial in patients with the most severe pulmonary dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/56\">",
"     56",
"    </a>",
"    ]. The specialized delivery systems adapted for continuous nebulization are described above. (See",
"    <a class=\"local\" href=\"#H10617078\">",
"     'Continuous nebulization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patients with tracheostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques have been developed for the delivery of aerosol medication by nebulizer or MDI to patients with a tracheostomy tube who are not ventilator dependent (",
"    <a class=\"graphic graphic_picture graphicRef70613 \" href=\"UTD.htm?11/46/12000\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/58\">",
"     58",
"    </a>",
"    ]. Two systems are available for delivery of nebulized medication: either a mask can be placed over the tracheostomy opening or the nebulizer chamber can be attached to the tracheostomy tube using a T-piece made of ventilator tubing and a connector. The T-piece approach is preferred because more aerosol is directed into the tracheostomy tube.",
"   </p>",
"   <p>",
"    For delivery of an MDI aerosol, the canister is removed from its usual plastic actuator and inserted into an",
"    <span class=\"nowrap\">",
"     actuator/spacer",
"    </span>",
"    that is attached by T-shaped connector to the tracheostomy tube. This",
"    <span class=\"nowrap\">",
"     actuator/spacer",
"    </span>",
"    is the same as that used for patients on mechanical ventilation (",
"    <a class=\"graphic graphic_picture graphicRef53295 \" href=\"UTD.htm?5/12/5327\">",
"     picture 6",
"    </a>",
"    ). The caregiver actuates the MDI into the spacer and the patient inhales the aerosol through the tracheostomy tube.",
"   </p>",
"   <p>",
"    Adaptations have not been developed for effective administration of medication from DPIs into tracheostomy tubes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mechanically ventilated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors affect aerosol delivery during mechanical ventilation (",
"    <a class=\"graphic graphic_table graphicRef64944 \" href=\"UTD.htm?10/28/10699\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/59-69\">",
"     59-69",
"    </a>",
"    ]. One major factor is that humidification of inhaled gas decreases aerosol deposition by approximately 40 percent due to increased particle drug deposition in the ventilator circuit. For this reason, increased dosage of medication is often required to achieve a therapeutic effect in mechanically ventilated patients.",
"   </p>",
"   <p>",
"    Inhaled medications can be delivered to patients receiving mechanical ventilation using either an MDI or a nebulizer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. A DPI",
"    <strong>",
"     cannot",
"    </strong>",
"    be used to deliver dry powder during mechanical ventilation because ventilator circuit humidification impairs aerosol formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Metered dose inhaler",
"    </span>",
"    &nbsp;&mdash;&nbsp;A special actuator is needed to adapt the MDI into the ventilator circuit (",
"    <a class=\"graphic graphic_picture graphicRef53295 \" href=\"UTD.htm?5/12/5327\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. The size, shape, and design of these actuators have a major impact on drug delivery to the patient. An MDI with a chamber results in a four- to six-fold greater delivery of aerosol than MDI actuation into a connector attached directly to the endotracheal tube, or into an in-line device that lacks a chamber [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/62\">",
"     62",
"    </a>",
"    ]. When using an MDI during mechanical ventilation, it is important to synchronize actuation with inspiratory airflow to optimize drug delivery. Properly used, an MDI may deliver a more consistent dose than a nebulizer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following technique has been proposed for using MDIs in mechanically ventilated adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shake the MDI vigorously",
"     </li>",
"     <li>",
"      Place canister in the actuator of a cylindrical spacer situated in the inspiratory limb of ventilator circuit (",
"      <a class=\"graphic graphic_picture graphicRef53295 \" href=\"UTD.htm?5/12/5327\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Actuate the MDI once only with the onset of inspiration by the ventilator",
"     </li>",
"     <li>",
"      Repeat actuations after 20 to 30 seconds until the total dose is delivered",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Helium-oxygen mixtures affect aerosol deposition, and in vitro modeling has reported a 50 percent increase in deposition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    from an MDI during mechanical ventilation when heliox was used as the driving gas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/74\">",
"     74",
"    </a>",
"    ]. However, heliox can interfere with the functioning of flow sensors and oxygen levels when delivered through some ventilators, and care must be taken if this approach is employed with a ventilator that is not approved for heliox administration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link&amp;anchor=H21#H21\">",
"     \"Physiology and clinical use of heliox\", section on 'Instrument sensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of a heat and moisture exchanger (HME) in the ventilator circuit can filter out the aerosol when an MDI (or nebulizer) is used. Commercially available devices can be used to bypass the HME when a MDI is used (",
"    <a class=\"graphic graphic_picture graphicRef50376 \" href=\"UTD.htm?1/52/1856\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80294 \" href=\"UTD.htm?10/37/10847\">",
"     picture 8",
"    </a>",
"    ). Alternatively, the HME must be removed from the circuit when the aerosol is delivered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Nebulizer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal methods for delivery of nebulized medication to mechanically ventilated patients are not well-established. Delivery of a large tidal volume, use of an end-inspiratory pause, and use of a slow inspiratory flow affect aerosol delivery by nebulizer but",
"    <strong>",
"     not",
"    </strong>",
"    by MDI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/59\">",
"     59",
"    </a>",
"    ]. Nebulizer performance can be optimized by placing the nebulizer 30 cm from the endotracheal tube, rather than at the Y-piece, because the inspiratory ventilator tubing acts as a spacer. In a simulation model, delivery of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    via mesh nebulizer was two to four times greater than with a jet nebulizer, and placement of the mesh nebulizer in the ventilator tubing on the ventilator side of the humidifier, rather than closer to the patient, increased drug delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/64\">",
"     64",
"    </a>",
"    ]. However, this approach has not been commonly adopted.",
"   </p>",
"   <p>",
"    Operating the nebulizer only during inspiration is more efficient for aerosol delivery compared with continuous aerosol generation throughout the respiratory cycle. When a breath-actuated nebulizer is used, the delivered dose increases by more than five-fold. In addition, when the humidifier is bypassed the delivered dose increases by a factor of nearly four [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages of nebulizer use during mechanical ventilation include circuit contamination due to interrupting the ventilator tubing circuit, decreased ability of the patient to trigger the ventilator, and the associated increases in tidal volume and airway pressure due to nebulizer flow. Valved T-piece devices are commercially available and commonly used to allow the nebulizer to be inserted within the ventilator circuit without disconnecting the patient from the ventilator, thus avoiding interruption of mechanical ventilation for nebulizer insertion and removal (",
"    <a class=\"graphic graphic_picture graphicRef71363 \" href=\"UTD.htm?12/46/13024\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=see_link\">",
"     \"The ventilator circuit and ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Choice of device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the nebulizer is less efficient than the MDI during mechanical ventilation, the nebulizer can deliver a greater cumulative dose to the lower respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/78\">",
"     78",
"    </a>",
"    ]. Thus, nebulizers and MDIs produce similar therapeutic effects in mechanically ventilated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/79\">",
"     79",
"    </a>",
"    ]. The use of an MDI for routine bronchodilator therapy in ventilator-supported patients is preferred because of the problems associated with the use of nebulizers, including contamination and triggering difficulty, as well as increased pressure and volume delivery.",
"   </p>",
"   <p>",
"    Aerosol delivery by MDI is easy to administer, involves less personnel time, provides a reliable dose of the drug, and is free from the risk of bacterial contamination. When an MDI is used with an in-line spacer, the ventilator circuit does not need to be disconnected with each treatment; this may reduce the risk of ventilator-associated pneumonia. This also prevents the loss of positive end-expiratory pressure (PEEP) in patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=see_link\">",
"     \"The ventilator circuit and ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aerosol therapy can also be administered during noninvasive positive pressure ventilation (NPPV), using devices adapted for inline administration (",
"    <a class=\"graphic graphic_picture graphicRef79663 \" href=\"UTD.htm?15/13/15570\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. Effective delivery of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    by MDI during NPPV using a specialized spacer has been reported in patients with exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20210883\">",
"    <span class=\"h2\">",
"     Home use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescription of a nebulizer for home use is usually not necessary for patients with asthma or COPD due to the efficacy of MDIs and DPIs for delivery of bronchodilator medications. However, some patients (eg, those with difficulty mastering the technique of MDIs) may have a better response to a nebulizer. The decision to prescribe a nebulizer for home use is made on a case-by-case basis. Careful instructions are provided regarding indications for coming to the emergency department if one or two nebulizer treatments do not result in reduced symptoms.",
"   </p>",
"   <p>",
"    Typically, jet nebulizers are provided for patients with asthma or COPD unless the patient is willing to pay extra for a smaller, more portable mesh nebulizer. For patients requiring specialized medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    suspension,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , DNase I,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    the selection of a nebulizer device depends on the requirements of the particular medication, as described above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Nebulizers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With a jet nebulizer, the patient also needs an air compressor in addition to the nebulizer, tubing, and mouthpiece. Although the nebulizer is disposable, many patients re-use it multiple times before replacing. Proper cleaning and air-drying of the nebulizer chamber and mouthpiece are needed to prevent bacterial and fungal colonization and also contamination by allergens, such as dust mites, cockroach, and dander. The plastic tubing and medication chamber should be stored in a plastic bag between uses. Once or twice a week, the nebulizer (",
"    <a class=\"graphic graphic_figure graphicRef57284 \" href=\"UTD.htm?33/44/34496\">",
"     figure 1",
"    </a>",
"    ) should be disassembled, washed in soapy tap water, and disinfected with either a 1.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    (white vinegar) mixture or a quaternary ammonium compound at a dilution of 1 ounce to 1 gallon of sterile of distilled water. The acetic acid soak should be at least 1 hour, but a quaternary ammonium compound soak needs only 10 minutes. However, patients with asthma should avoid breathing the fumes of these cleaning agents.",
"   </p>",
"   <p>",
"    Ultrasonic and mesh nebulizers should be cleaned and disinfected per the manufacturer&rsquo;s specifications.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     Acetic acid",
"    </a>",
"    should not be reused, but the quaternary ammonium solution can be reused for up to one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=see_link\">",
"       \"Patient information: How to use your dry powder inhaler (adults) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=see_link\">",
"       \"Patient information: Inhalers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"       \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective delivery of inhaled medications requires selection of the appropriate drug, proper use of the delivery device, education of the patient in the correct use of the device, and patient compliance. Frequent review of the proper use of the device is crucial. All health care professionals interacting with the patient share responsibility for this teaching and should personally understand the correct use of the various devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Available devices",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three principal types of devices are used to deliver inhaled medications: pressurized metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. A comparison of delivery devices for inhaled medications is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef71527 \" href=\"UTD.htm?17/10/17581\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An MDI consists of a pressurized canister, a metering valve and stem, and a mouthpiece actuator (",
"      <a class=\"graphic graphic_picture graphicRef62613 \" href=\"UTD.htm?37/43/38591\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/20/18762/abstract/15\">",
"       15",
"      </a>",
"      ]. DPIs create aerosols by drawing air through a dose of powdered medication (",
"      <a class=\"graphic graphic_picture graphicRef57922 \" href=\"UTD.htm?41/43/42675\">",
"       picture 2",
"      </a>",
"      ). The correct techniques for using MDIs and DPIs are reviewed separately. (See",
"      <a class=\"local\" href=\"#H339815\">",
"       'Metered dose inhalers (MDI)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"       \"The use of inhaler devices in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"       \"The use of inhaler devices in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most commonly-used type of nebulizer is the jet (or pneumatic) nebulizer (",
"      <a class=\"graphic graphic_figure graphicRef57284 \" href=\"UTD.htm?33/44/34496\">",
"       figure 1",
"      </a>",
"      ); mesh and ultrasonic nebulizers are also available. Nebulizer performance is affected by technical factors, such as mechanism of aerosol generation and drug formulation (not all medications can be used with all nebulizers), as well as patient-related factors (",
"      <a class=\"graphic graphic_table graphicRef58515 \" href=\"UTD.htm?32/24/33163\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nebulizers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With all of the standard nebulizers, patients should be encouraged to use a slow breathing pattern with an occasional deep breath. We generally favor the use of mouthpieces over face masks, as the latter are associated with some facial and eye deposition of aerosol. (See",
"      <a class=\"local\" href=\"#H339955\">",
"       'Mouthpieces and facemasks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mesh nebulizers force a solution or suspension of medication through a mesh to produce an aerosol, without need for an internal baffling system or compressed air source. These devices are quiet, portable, and able to generate aerosols with a high fine-particle fraction, resulting in more efficient drug delivery. (See",
"      <a class=\"local\" href=\"#H339423\">",
"       'Mesh nebulizers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasonic nebulizers transmit ultrasonic waves to the surface of the solution to create an aerosol, which is delivered to the patient by a fan or by the inspiratory flow generated by the patient&rsquo;s breath. They are quieter than jet nebulizers, but cannot be used to deliver a drug in suspension. (See",
"      <a class=\"local\" href=\"#H339430\">",
"       'Ultrasonic nebulizers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newer nebulizer designs to reduce drug wastage include breath-actuated devices that deliver the majority of the medication during inhalation and storage bag nebulizers. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Enhanced nebulizer designs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Options for specific patient situations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For spontaneously breathing patients, there are advantages and disadvantages to each aerosol delivery device (",
"      <a class=\"graphic graphic_table graphicRef71527 \" href=\"UTD.htm?17/10/17581\">",
"       table 1",
"      </a>",
"      ). However, MDIs, DPIs, and nebulizers are all effective for treatment of asthma and COPD when used correctly. Thus, we advise selecting a delivery device based upon the desired beta agonist or glucocorticoid, convenience, cost, clinician and patient preferences, and the patient&rsquo;s ability to use the device correctly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a mild to moderate exacerbation of asthma, beta-2 agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ) may be administered either by nebulizer or by MDI combined with a spacer or chamber device. For patients with a severe exacerbation of asthma not requiring mechanical ventilation, we suggest delivery of inhaled beta-2 agonists by nebulizer rather than MDI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Use of a nebulizer for a severe asthma exacerbation may be intermittent (every 20 to 30 minutes) or continuous. The doses of beta-2 agonists for these applications are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H340028\">",
"       'Acute asthma exacerbation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10617078\">",
"       'Continuous nebulization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some drug preparations are only approved for delivery with specific nebulizers due to factors such as preventing contamination of the ambient environment, achieving greater precision in dosing, or preventing medication degradation by the aerosol technology. Examples of medications requiring specific nebulizers include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       Ribavirin",
"      </a>",
"      , DNase I,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H24790161\">",
"       'Nebulizers for specific medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of medication aerosols by MDI or nebulizer to a spontaneously breathing patient with a tracheostomy tube requires use of adaptive devices; examples are provided in the figure (",
"      <a class=\"graphic graphic_picture graphicRef70613 \" href=\"UTD.htm?11/46/12000\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patients with tracheostomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For mechanically-ventilated patients who require aerosol medication, we suggest the use of MDIs combined with a specialized spacer that is placed in the ventilator tubing, rather than use of a nebulizer (",
"      <a class=\"graphic graphic_picture graphicRef53295 \" href=\"UTD.htm?5/12/5327\">",
"       picture 6",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The MDI method is technically easier than nebulizer treatments, involves less personnel time, provides a reliable dose of the drug, and reduces the risk of bacterial contamination that can occur with a nebulizer. The same adaptations can be used to deliver inhaled medications to patients receiving noninvasive positive pressure ventilation (NPPV). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Mechanically ventilated patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/1\">",
"      Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008; 53:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/2\">",
"      Olschewski H, Simonneau G, Gali&egrave; N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/3\">",
"      Furyk JS, Grabowski WJ, Black LH. Nebulized fentanyl versus intravenous morphine in children with suspected limb fractures in the emergency department: a randomized controlled trial. Emerg Med Australas 2009; 21:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/4\">",
"      Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage 2009; 38:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/5\">",
"      Nejmi H, Fath K, Anaflous R, et al. [A prospective randomized comparison of nebulized morphine versus thoracic epidural analgesia in the management of thoracic trauma]. Ann Fr Anesth Reanim 2010; 29:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/6\">",
"      Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/7\">",
"      Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001; 323:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/8\">",
"      Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/9\">",
"      Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997; 157:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/10\">",
"      Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006; :CD000052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/11\">",
"      Frei SP. Cost comparison of bronchodilator delivery methods in Emergency Department treatment of asthma. J Emerg Med 2000; 19:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/12\">",
"      Turner MO, Gafni A, Swan D, FitzGerald JM. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med 1996; 156:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/13\">",
"      Ram FS, Wright J, Brocklebank D, White JE. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma. BMJ 2001; 323:901.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program. Expert panel report III: Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute (NIH publication no. 08-4051), Bethesda, MD 2007, www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/15\">",
"      Newman SP. Principles of metered-dose inhaler design. Respir Care 2005; 50:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/16\">",
"      Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 2000; 45:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/17\">",
"      Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/18\">",
"      Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005; 50:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/19\">",
"      Hess DR. Nebulizers: principles and performance. Respir Care 2000; 45:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/20\">",
"      Rau JL. Design principles of liquid nebulization devices currently in use. Respir Care 2002; 47:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/21\">",
"      Leung K, Louca E, Coates AL. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 2004; 126:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/22\">",
"      Hess D, Fisher D, Williams P, et al. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996; 110:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/23\">",
"      Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000; 45:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/24\">",
"      Burchett DK, Darko W, Zahra J, et al. Mixing and compatibility guide for commonly used aerosolized medications. Am J Health Syst Pharm 2010; 67:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/25\">",
"      Camargo CA Jr, Rachelefsky G, Schatz M. Managing asthma exacerbations in the emergency department: summary of the National Asthma Education And Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. Proc Am Thorac Soc 2009; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/26\">",
"      Standaert TA, Vandevanter D, Ramsey BW, et al. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/27\">",
"      Standaert TA, Bohn SE, Aitken ML, Ramsey B. The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 2001; 14:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/28\">",
"      Reisner C, Katial RK, Bartelson BB, et al. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001; 86:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/29\">",
"      Hess DR, Acosta FL, Ritz RH, et al. The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999; 115:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/30\">",
"      Kress JP, Noth I, Gehlbach BK, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med 2002; 165:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/31\">",
"      Henderson SO, Acharya P, Kilaghbian T, et al. Use of heliox-driven nebulizer therapy in the treatment of acute asthma. Ann Emerg Med 1999; 33:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/32\">",
"      Anderson, M, Svartengren, M, Philipson, K, et al. Deposition in man of particles suspended in air or in helium-oxygen mixture at different flow rates. J Aerosol Med 1990; 3:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/33\">",
"      Anderson M, Svartengren M, Bylin G, et al. Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am Rev Respir Dis 1993; 147:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/34\">",
"      Habib DM, Garner SS, Brandeburg S. Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model. Pharmacotherapy 1999; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/35\">",
"      Svartengren M, Anderson M, Philipson K, Camner P. Human lung deposition of particles suspended in air or in helium/oxygen mixture. Exp Lung Res 1989; 15:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/36\">",
"      Berlinski A, Waldrep JC. Four hours of continuous albuterol nebulization. Chest 1998; 114:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/37\">",
"      McPeck M, Tandon R, Hughes K, Smaldone GC. Aerosol delivery during continuous nebulization. Chest 1997; 111:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/38\">",
"      Reisner C, Lee J, Kotch A, Dworkin G. Comparison of volume output from two different continuous nebulizer systems. Ann Allergy Asthma Immunol 1996; 76:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/39\">",
"      Berlinski A, Willis JR, Leisenring T. In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization. Respir Care 2010; 55:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/40\">",
"      Dhand R. New frontiers in aerosol delivery during mechanical ventilation. Respir Care 2004; 49:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/41\">",
"      Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 2008; 5:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/42\">",
"      Hardaker LE, Hatley RH. In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system. J Aerosol Med Pulm Drug Deliv 2010; 23 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/43\">",
"      Denyer J, Dyche T. The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future. J Aerosol Med Pulm Drug Deliv 2010; 23 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/44\">",
"      Skaria S, Smaldone GC. Omron NE U22: Comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 2010; 23:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/45\">",
"      Yeo LY, Friend JR, McIntosh MP, et al. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin Drug Deliv 2010; 7:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/46\">",
"      Berger W. Aerosol devices and asthma therapy. Curr Drug Deliv 2009; 6:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/47\">",
"      Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care 2004; 49:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/48\">",
"      Sabato K, Ward P, Hawk W, et al. Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respir Care 2011; 56:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/49\">",
"      Sangwan S, Gurses BK, Smaldone GC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004; 37:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/50\">",
"      Ari A, Harwood R, Sheard M, et al. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol 2011; 46:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/51\">",
"      Bhashyam AR, Wolf MT, Marcinkowski AL, et al. Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv 2008; 21:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/52\">",
"      Coates AL, MacNeish CF, Meisner D, et al. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997; 111:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/53\">",
"      MacNeish CF, Meisner D, Thibert R, et al. A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) Respirator Solution. Chest 1997; 111:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/54\">",
"      Flament MP, Leterme P, Burnouf T, Gayot A. Influence of formulation on jet nebulisation quality of alpha 1 protease inhibitor. Int J Pharm 1999; 178:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/55\">",
"      Hess DR. Liquid nebulization: emerging technologies conference summary. Respir Care 2002; 47:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/56\">",
"      Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/57\">",
"      Rodrigo GJ, Rodrigo C. Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 2002; 122:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/58\">",
"      Piccuito CM, Hess DR. Albuterol delivery via tracheostomy tube. Respir Care 2005; 50:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/59\">",
"      Hess D. Aerosol delivery during mechanical ventilation. Minerva Anestesiol 2002; 68:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/60\">",
"      Miller DD, Amin MM, Palmer LB, et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003; 168:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/61\">",
"      Georgopoulos D, Mouloudi E, Kondili E, Klimathianaki M. Bronchodilator delivery with metered-dose inhaler during mechanical ventilation. Crit Care 2000; 4:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/62\">",
"      Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 2008; 21:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/63\">",
"      Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008; 29:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/64\">",
"      Ari A, Atalay OT, Harwood R, et al. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 2010; 55:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/65\">",
"      Guerin C, Fassier T, Bayle F, et al. Inhaled bronchodilator administration during mechanical ventilation: how to optimize it, and for which clinical benefit? J Aerosol Med Pulm Drug Deliv 2008; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/66\">",
"      Dhand R. Basic techniques for aerosol delivery during mechanical ventilation. Respir Care 2004; 49:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/67\">",
"      Ari A, Areabi H, Fink JB. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir Care 2010; 55:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/68\">",
"      Dhand R, Sohal H. Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008; 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/69\">",
"      Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care 2007; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/70\">",
"      Dhand R, Duarte AG, Jubran A, et al. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1996; 154:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/71\">",
"      Lin HL, Fink JB, Zhou Y, Cheng YS. Influence of moisture accumulation in inline spacer on delivery of aerosol using metered-dose inhaler during mechanical ventilation. Respir Care 2009; 54:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/72\">",
"      Hess DR, Dillman C, Kacmarek RM. In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive Care Med 2003; 29:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/73\">",
"      Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med 1997; 156:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/74\">",
"      Goode ML, Fink JB, Dhand R, Tobin MJ. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med 2001; 163:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/75\">",
"      Tassaux D, Jolliet P, Thouret JM, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/76\">",
"      Devabhaktuni VG, Torres A Jr, Wilson S, Yeh MP. Effect of nitric oxide, perfluorocarbon, and heliox on minute volume measurement and ventilator volumes delivered. Crit Care Med 1999; 27:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/77\">",
"      Oppenheim-Eden A, Cohen Y, Weissman C, Pizov R. The effect of helium on ventilator performance: study of five ventilators and a bedside Pitot tube spirometer. Chest 2001; 120:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/78\">",
"      Marik P, Hogan J, Krikorian J. A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients. Chest 1999; 115:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/79\">",
"      Duarte AG, Momii K, Bidani A. Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically ventilated patients: comparison of magnitude and duration of response. Respir Care 2000; 45:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/80\">",
"      Chatmongkolchart S, Schettino GP, Dillman C, et al. In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. Crit Care Med 2002; 30:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/81\">",
"      Branconnier MP, Hess DR. Albuterol delivery during noninvasive ventilation. Respir Care 2005; 50:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/82\">",
"      Hess DR. The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J Aerosol Med 2007; 20 Suppl 1:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/83\">",
"      Pollack CV Jr, Fleisch KB, Dowsey K. Treatment of acute bronchospasm with beta-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Ann Emerg Med 1995; 26:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/20/18762/abstract/84\">",
"      Nava S, Karakurt S, Rampulla C, et al. Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study. Intensive Care Med 2001; 27:1627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 552 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18762=[""].join("\n");
var outline_f18_20_18762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H339815\">",
"      METERED DOSE INHALERS (MDI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H339674\">",
"      DRY POWDER INHALERS (DPI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEBULIZERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339203\">",
"      Jet nebulizers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H339577\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10616854\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20150710\">",
"      - Factors affecting drug delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10617078\">",
"      - Continuous nebulization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339423\">",
"      Mesh nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339430\">",
"      Ultrasonic nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Enhanced nebulizer designs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339955\">",
"      Mouthpieces and facemasks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H339088\">",
"      AEROSOL DELIVERY IN SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24790161\">",
"      Nebulizers for specific medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H340028\">",
"      Acute asthma exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patients with tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mechanically ventilated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Metered dose inhaler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Nebulizer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Choice of device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20210883\">",
"      Home use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Available devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Options for specific patient situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/552\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/552|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/62/26600\" title=\"algorithm 1\">",
"      Emergency Rx severe asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/552|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/44/34496\" title=\"figure 1\">",
"      Jet or pneumatic nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/63/37886\" title=\"figure 2\">",
"      Face mask delivery Beta agonist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/6/34927\" title=\"figure 3\">",
"      Aeroneb Solo mesh nebulizer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/3/37951\" title=\"figure 4\">",
"      Mesh nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/56/23439\" title=\"figure 5\">",
"      Nebulizer iNeb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/552|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/43/38591\" title=\"picture 1\">",
"      Metered dose inhaler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/43/42675\" title=\"picture 2\">",
"      Dry powder inhalers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/62/4079\" title=\"picture 3\">",
"      Aeroneb Go mesh nebulizer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/45/2770\" title=\"picture 4\">",
"      Nebulizers new designs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/46/12000\" title=\"picture 5\">",
"      MDI use with trach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/12/5327\" title=\"picture 6\">",
"      MDI in-line spacer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/52/1856\" title=\"picture 7\">",
"      HME selection device for mechanical ventilator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/37/10847\" title=\"picture 8\">",
"      Circuvent device for delivery of MDI or nebulized medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/46/13024\" title=\"picture 9\">",
"      Valved T-adaptor for nebulization during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/13/15570\" title=\"picture 10\">",
"      Neb or MDI use with NPPV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/552|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/10/17581\" title=\"table 1\">",
"      Aerosol device comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/34/15917\" title=\"table 2\">",
"      Doses beta agonist preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 3\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/48/38668\" title=\"table 4\">",
"      Usual doses inhaled GC-LABA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/24/33163\" title=\"table 5\">",
"      Nebulizer performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/37/14939\" title=\"table 6\">",
"      Nebulizer technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/53/11100\" title=\"table 7\">",
"      Inhaled medications that require specific nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/28/10699\" title=\"table 8\">",
"      Aerosol delivery ventilator",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=related_link\">",
"      Respiratory syncytial virus infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=related_link\">",
"      The ventilator circuit and ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_20_18763="Early signs of autism";
var content_f18_20_18763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Early signs of autism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gaze",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of appropriate gaze",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of warm, joyful expressions with gaze",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Receptive language",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of recognition of mother's, father's, or consistent caregiver's voice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of response to name",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased awareness of environmental sounds",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of interest in or response to comments made by others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Expressive language",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of to-and-fro pattern of vocalization that typically occurs by about 6 months of age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Delayed onset of babbling (after 9 months of age)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of expressions such as \"oh-oh\" or \"huh\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pre-speech gestures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased or absent use of pre-speech gestures, such as waving, pointing, showing",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18763=[""].join("\n");
var outline_f18_20_18763=null;
var title_f18_20_18764="Broad behavior screens II";
var content_f18_20_18764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected broad-band behavior screens-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test/age range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purchasing information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time frame*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Eyberg Child Behavior Inventory/Sutter-Eyberg Student Behavior Inventory-Revised (ECBI/SESBI-R)",
"         </strong>",
"        </p>",
"        <p>",
"         2 to 16",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Psychological Assessment Resources",
"        </p>",
"        <p>",
"         P.O. Box 998",
"        </p>",
"        <p>",
"         Odessa, FL 33556",
"        </p>",
"        <p>",
"         Phone: 800.331.8378",
"        </p>",
"        <p>",
"         <a href=\"file://www.parinc.com\" target=\"_blank\">",
"          www.parinc.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $120 (includes professional manual, 50 ECBI and 50 SESBI-R test sheets).",
"        </p>",
"       </td>",
"       <td>",
"        About 5 minutes (if interview needed)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Parents' Evaluations of Developmental Status (PEDS) (2010)",
"         </strong>",
"        </p>",
"        <p>",
"         Birth to 8 years",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         PEDS",
"         <em>",
"          Test",
"         </em>",
"         .com, LLC",
"        </p>",
"        <p>",
"         1013 Austin Court",
"        </p>",
"        <p>",
"         Nolensville, TN 37135",
"        </p>",
"        <p>",
"         Phone: 615.776.4121",
"        </p>",
"        <p>",
"         Fax: 615.776.4119",
"        </p>",
"        <p>",
"         <a href=\"file://www.pedstest.com\" target=\"_blank\">",
"          www.pedstest.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $30 (includes 50 response forms, 50 score and interpretation forms, and one brief administration and scoring guide).",
"        </p>",
"       </td>",
"       <td>",
"        About 2 minutes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Pediatric Symptom Checklist (PSC) and Pictorial Pediatric Symptom Checklist",
"         </strong>",
"        </p>",
"        <p>",
"         4 to 16 years",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Can be downloaded for free at:",
"        </p>",
"        <p>",
"         <a href=\"file://www2.massgeneral.org/allpsych/psc/psc_forms.htm\" target=\"_blank\">",
"          www2.massgeneral.org/allpsych/psc/psc_forms.htm",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        About 3 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Does not include score time.",
"    </div>",
"    <div class=\"reference\">",
"     Frances Page Glascoe, 2011, Nolensville, TN: PEDSTest.com, LLC, www.pedstest.com. Adapted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18764=[""].join("\n");
var outline_f18_20_18764=null;
var title_f18_20_18765="Causes of chronic MR";
var content_f18_20_18765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of chronic mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Leaflet",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Myxomatous valve disease (mitral valve prolapse)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Rheumatic fever",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Infective endocarditis (acute and chronic)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Systemic inflammatory disorders",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Systemic lupus erythematosus",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Scleroderma",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Connective tissue disorders",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Marfan's",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Ehlers-Danlos",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Pseudoxanthoma elasticum",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Congenital",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Mitral valve clefts",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Parachute mitral valve",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Endocardial cushion defects",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Hypertrophic cardiomyopathy (systolic anterior movement of mitral valve)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Drug-related",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Chordae tendineae",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Myxomatous valve disease (mitral valve prolapse)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Infective endocarditis (acute and chronic)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Rheumatic fever",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Spontaneous rupture",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Myocardial infarction",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Trauma",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Papillary muscles",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Ischemia or infarction",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Dilated cardiomyopathy",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Left ventricular aneurysm",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Papillary muscle rupture",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Myocardial infarction",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Trauma",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Mitral annulus",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Calcification",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Idiopathic",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Rheumatic fever",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Chronic renal failure",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Hyperparathyroidism",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Dilatation",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Connective tissue disorder",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Dilated cardiomyopathy",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Myxomatous mitral valve disease",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Prosthetic valve",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Paravalvular leak",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Infective endocarditis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Ring or strut fracture",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Occluder dysfunction or dislodgement",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Pannus formation",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Leaflet deterioration (tissue valves)",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18765=[""].join("\n");
var outline_f18_20_18765=null;
var title_f18_20_18766="Pleural effusions in HIV I";
var content_f18_20_18766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58777%7EPULM%2F71626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58777%7EPULM%2F71626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pleural effusions in HIV: Differential diagnosis and diagnostic testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Etiology",
"      </td>",
"      <td class=\"subtitle1\">",
"       History/physical exam/lab findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pleural fluid characteristics",
"      </td>",
"      <td class=\"subtitle1\">",
"       Additional tests of pleural fluid",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other helpful tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parapneumonic effusion",
"      </td>",
"      <td>",
"       Short duration of symptoms suggesting infection; parenchymal opacities on chest radiograph",
"      </td>",
"      <td>",
"       <p>",
"        Low pH",
"       </p>",
"       <p>",
"        Increased neutrophils",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Blood culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Septic embolism",
"      </td>",
"      <td>",
"       Intravenous drug abuse",
"      </td>",
"      <td>",
"       Exudative",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Blood culture",
"       </p>",
"       <p>",
"        Echocardiogram",
"       </p>",
"       <p>",
"        Chest CT may show multiple nodules",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumocystis jirovecii",
"      </td>",
"      <td>",
"       <p>",
"        Fever",
"       </p>",
"       <p>",
"        Dyspnea",
"       </p>",
"       <p>",
"        Inhaled pentamidine prophylaxis",
"       </p>",
"       <p>",
"        Low CD 4",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Small to moderate effusion",
"       </p>",
"       <p>",
"        Serous or sanguinous",
"       </p>",
"       <p>",
"        Lymphocytic",
"       </p>",
"       <p>",
"        Eosinophilic aggregates",
"       </p>",
"       <p>",
"        LDH increased",
"       </p>",
"      </td>",
"      <td>",
"       Grocott silver for P. jiroveci cysts or Diff-Quik for trophozoites",
"      </td>",
"      <td>",
"       Induced sputum or bronchoalveolar lavage for P. jiroveci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterial disease",
"      </td>",
"      <td>",
"       <p>",
"        History of exposure",
"       </p>",
"       <p>",
"        Residence in an endemic area",
"       </p>",
"       <p>",
"        Low CD4",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Lymphocytic effusion",
"       </p>",
"       <p>",
"        Adenosine deaminase &gt;50 U/L",
"       </p>",
"      </td>",
"      <td>",
"       Mycobacterial smear and culture",
"      </td>",
"      <td>",
"       <p>",
"        PPD",
"       </p>",
"       <p>",
"        Induced sputum",
"       </p>",
"       <p>",
"        Pleural biopsy for culture and identification of granulomas",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nocardia",
"      </td>",
"      <td>",
"       <p>",
"        Acute or subacute onset of fever, night sweats, fatigue, anorexia, cough, dyspnea",
"       </p>",
"       <p>",
"        Low CD 4",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Modified Kinyoun acid fast stain",
"       </p>",
"       <p>",
"        PCR for Nocardia",
"       </p>",
"       <p>",
"        Maintain aerobic culture for 5 to 21 days",
"       </p>",
"      </td>",
"      <td>",
"       Blood culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cryptococcus",
"      </td>",
"      <td>",
"       <p>",
"        Fever, cough, dyspnea",
"       </p>",
"       <p>",
"        CD4 &lt;100/microL",
"       </p>",
"      </td>",
"      <td>",
"       Serous exudate",
"      </td>",
"      <td>",
"       <p>",
"        Cryptococcal antigen",
"       </p>",
"       <p>",
"        Cryptococcal culture (positive in 42 percent)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Serum cryptococcal antigen",
"       </p>",
"       <p>",
"        Pleural biopsy",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histoplasma",
"      </td>",
"      <td>",
"       <p>",
"        History of residing in endemic area",
"       </p>",
"       <p>",
"        Subacute febrile illness",
"       </p>",
"      </td>",
"      <td>",
"       Serous or serosanguinous effusion",
"      </td>",
"      <td>",
"       Wright-Giemsa stain for intracellular Histoplasma yeast forms",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Toxoplasma",
"      </td>",
"      <td>",
"       <p>",
"        Usually evidence of disseminated toxoplasmosis",
"       </p>",
"       <p>",
"        CD4 &lt;100 cells/microL",
"       </p>",
"      </td>",
"      <td>",
"       Unilateral or bilateral",
"      </td>",
"      <td>",
"       Giemsa stain for tachyzoites within neutrophils",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leishmaniasis",
"      </td>",
"      <td>",
"       <p>",
"        Fever",
"       </p>",
"       <p>",
"        Leukopenia",
"       </p>",
"       <p>",
"        Lymphopenia",
"       </p>",
"       <p>",
"        Thrombocytopenia",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Serologic studies positive in 50 percent",
"       </p>",
"       <p>",
"        Peripheral smear",
"       </p>",
"       <p>",
"        Bone marrow smear positive 67 percent",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pleural effusions in HIV: Differential diagnosis and diagnostic testing (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Etiology",
"      </td>",
"      <td class=\"subtitle1\">",
"       History/physical exam/lab findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pleural fluid characteristics",
"      </td>",
"      <td class=\"subtitle1\">",
"       Additional tests of pleural fluid",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other helpful tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kaposi sarcoma (KS) associated effusion",
"      </td>",
"      <td>",
"       <p>",
"        Skin lesions of KS",
"       </p>",
"       <p>",
"        No pleuritic pain",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Large to massive, bilateral effusion(s)",
"       </p>",
"       <p>",
"        Hemorrhagic fluid",
"       </p>",
"      </td>",
"      <td>",
"       Cytology is negative",
"      </td>",
"      <td>",
"       <p>",
"        Chest radiograph: diffuse pulmonary opacities",
"       </p>",
"       <p>",
"        Endobronchial lesions of KS",
"       </p>",
"       <p>",
"        Pleural biopsy is negative",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multicentric Castleman disease",
"      </td>",
"      <td>",
"       <p>",
"        Fever",
"       </p>",
"       <p>",
"        Cough, dyspnea in 60 percent",
"       </p>",
"       <p>",
"        Peripheral lymphadenopathy",
"       </p>",
"       <p>",
"        Anemia",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Chest radiograph: reticular or nodular opacities",
"       </p>",
"       <p>",
"        Chest CT: mediastinal adenopathy as disease progresses",
"       </p>",
"       <p>",
"        Lymph node biopsy",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic lymphoma",
"      </td>",
"      <td>",
"       <p>",
"        Low CD4 level",
"       </p>",
"       <p>",
"        Serum LDH high",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Large, serosanguinous exudative effusion (may have mass effect)",
"       </p>",
"       <p>",
"        Pleural LDH high",
"       </p>",
"       <p>",
"        Cytology positive (60 percent)",
"       </p>",
"      </td>",
"      <td>",
"       Flow cytometry",
"      </td>",
"      <td>",
"       Pleural biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary effusion lymphoma",
"      </td>",
"      <td>",
"       <p>",
"        Low CD 4 count",
"       </p>",
"       <p>",
"        Preexisting KS in 30 percent",
"       </p>",
"      </td>",
"      <td>",
"       Pleural fluid cytology usually diagnostic",
"      </td>",
"      <td>",
"       <p>",
"        LANA-1 (HHV8) +",
"       </p>",
"       <p>",
"        Lymphocytes often:",
"       </p>",
"       <p>",
"        CD45 +/CD30 +/EMA -/T cell antigen -/LMP1 usually -",
"       </p>",
"       <p>",
"        Monoclonal B cell population by Southern blot",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Chest CT: adjacent parietal pleural thickening and absent lymphadenopathy",
"       </p>",
"       <p>",
"        Pericardial effusion and ascites (common)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thromboembolism",
"      </td>",
"      <td>",
"       Risk factor(s) for thromboembolism",
"      </td>",
"      <td>",
"       Exudative, may be serous or serosanguinous",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        d-Dimer (positive)",
"       </p>",
"       <p>",
"        CT pulmonary angiogram",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypoalbuminemia",
"      </td>",
"      <td>",
"       Bilateral peripheral edema",
"      </td>",
"      <td>",
"       Transudative",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Serum albumin (low)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heart failure",
"      </td>",
"      <td>",
"       <p>",
"        Chronic dyspnea",
"       </p>",
"       <p>",
"        Bilateral peripheral edema",
"       </p>",
"      </td>",
"      <td>",
"       Transudative",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Serum BNP (elevated)",
"       </p>",
"       <p>",
"        Echocardiogram",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EMA: epithelial membrane antigen; LANA-1: as latency-associated nuclear antigen, a latent HHV8 gene product; LMP1: latent membrane protein 1 of Epstein Barr virus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_20_18766=[""].join("\n");
var outline_f18_20_18766=null;
var title_f18_20_18767="Contents: Kidneys and urinary system";
var content_f18_20_18767=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Kidneys and urinary system",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Kidneys and urinary system",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bladder cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/21/39250\">",
"           Patient information: Bladder cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/12/31939\">",
"           Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15205\">",
"           Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/39/13939\">",
"           Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bladder problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/0/16386\">",
"           Patient information: Neurogenic bladder in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blood in the urine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10066\">",
"           Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/59/23474\">",
"           Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes insipidus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/55/43889\">",
"           Patient information: Diabetes insipidus (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24644\">",
"           Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diet",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/2/18467\">",
"           Patient information: Dialysis and diet (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/41/42640\">",
"           Patient information: Low potassium diet (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39890\">",
"           Patient information: Low sodium diet (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8722\">",
"           Patient information: Low-potassium diet (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/19/41266\">",
"           Patient information: Low-sodium diet (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fluid and electrolytes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/34/15906\">",
"           Patient information: Hyperkalemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/54/14177\">",
"           Patient information: Hypokalemia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/20/9537\">",
"           Patient information: Hyponatremia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/29/13777\">",
"           Patient information: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glomerular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/31/37363\">",
"           Patient information: Glomerular disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37426\">",
"           Patient information: Glomerular disease overview (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hydronephrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/5/37970\">",
"           Patient information: Hydronephrosis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/45/3794\">",
"           Patient information: Prenatal hydronephrosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         IgA nephropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/62/12257\">",
"           Patient information: IgA nephropathy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Interstitial nephritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15713\">",
"           Patient information: Acute interstitial nephritis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Kidney biopsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/14/30944\">",
"           Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Kidney cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19650\">",
"           Patient information: Brain metastases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/13/11474\">",
"           Patient information: Kidney cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/14/30944\">",
"           Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/53/30546\">",
"           Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Kidney failure and dialysis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5859\">",
"           Patient information: Acute kidney failure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24850\">",
"           Patient information: Bone problems caused by kidney disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19107\">",
"           Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/5/13398\">",
"           Patient information: Chronic kidney disease (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/35/28212\">",
"           Patient information: Chronic kidney disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/2/18467\">",
"           Patient information: Dialysis and diet (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/26/9635\">",
"           Patient information: Dialysis or kidney transplantation  which is right for me? (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/57/40852\">",
"           Patient information: Hemodialysis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/1/25619\">",
"           Patient information: Hemodialysis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/46/25315\">",
"           Patient information: Kidney transplant (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8722\">",
"           Patient information: Low-potassium diet (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9188\">",
"           Patient information: Medicines for chronic kidney disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14501\">",
"           Patient information: Peritoneal dialysis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/43/16051\">",
"           Patient information: Peritoneal dialysis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12531\">",
"           Patient information: Planning for a kidney transplant (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/22/11619\">",
"           Patient information: Preparing for hemodialysis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Kidney stones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28499\">",
"           Patient information: Kidney stones in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/56/43905\">",
"           Patient information: Kidney stones in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/26/15779\">",
"           Patient information: Kidney stones in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27234\">",
"           Patient information: Kidney stones in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrotic syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/2/35875\">",
"           Patient information: The nephrotic syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycystic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/24/38277\">",
"           Patient information: Polycystic kidney disease (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/44/35523\">",
"           Patient information: Polycystic kidney disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protein in the urine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15921\">",
"           Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Swelling",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/53/32594\">",
"           Patient information: Edema (swelling) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21155\">",
"           Patient information: Swelling (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary catheters",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/53/4946\">",
"           Patient information: Using a catheter to empty the bladder (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/0/16386\">",
"           Patient information: Neurogenic bladder in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/0/19456\">",
"           Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/60/11202\">",
"           Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/56/35714\">",
"           Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/36/43586\">",
"           Patient information: Treatments for urge incontinence in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22658\">",
"           Patient information: Urinary incontinence (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35987\">",
"           Patient information: Urinary incontinence in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/16/9474\">",
"           Patient information: Urinary incontinence in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/19/19764\">",
"           Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28048\">",
"           Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/18/32036\">",
"           Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20210\">",
"           Patient information: Urinary tract infections in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/58/38818\">",
"           Patient information: Urinary tract infections in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10850\">",
"           Patient information: Urinary tract infections in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urine collection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21151\">",
"           Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/7/28799\">",
"           Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vesicoureteral reflux",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/8/6274\">",
"           Patient information: Vesicoureteral reflux in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-2F6766CF29-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_20_18767=[""].join("\n");
var outline_f18_20_18767=null;
